

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
26 August 2004 (26.08.2004)

PCT

(10) International Publication Number
WO 2004/071401 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/JP2004/001437
- (22) International Filing Date: 10 February 2004 (10.02.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
2003900587 11 February 2003 (11.02.2003) AU
- (74) Agent: **TAKASHIMA, Hajime**; Fujimura Yamato Seimei Bldg., 2-14, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410044 (JP).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (for all designated States except US): **FUJISAWA PHARMACEUTICAL CO., LTD.** [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418514 (JP).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **URANO, Yasuharu** [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418514 (JP). **HOSAKA, Mitsuru** [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418514 (JP). **KAMIJO, Kazunori** [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418514 (JP).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HDAC INHIBITOR



(57) Abstract: A compound having the following formula (I): wherein R₁ is lower alkyl optionally substituted with one or more suitable substituent(s); aryl optionally substituted with one or more suitable substituent(s); or fused ring, R₂ is acylamino or optionally protected hydroxy, L₁ is lower alkenylene, and R₃ is hydroxyamino, or a salt thereof. The compound is useful as an inhibitor of histone deacetylase.

WO 2004/071401 A2

BEST AVAILABLE COPY

DESCRIPTION

HDAC INHIBITOR

TECHNICAL FIELD


The present invention relates to a compound, which is
5 useful as a medicament, and to a pharmaceutical composition
comprising the same.

BACKGROUND ART

Histone deacetylase (hereinafter also referred as HDAC) is
known to play an essential role in the transcriptional machinery
10 for regulating gene expression, induce histone hyperacetylation
and to affect the gene expression. Therefore, it is useful as a
therapeutic or prophylactic agent for diseases caused by abnormal
gene expression, such as inflammatory disorders, diabetes,
diabetic complications, homozygous thalassemia, fibrosis,
15 cirrhosis, acute promyelocytic leukaemia (APL), organ transplant
rejections, autoimmune diseases, protozoal infections, tumors,
etc.

WO 01/38322 discloses an inhibitor of histone deacetylase
represented by the following formula:

20



wherein

Cy is cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which
is optionally substituted;


25 L^1 is $-(\text{CH}_2)_m\text{-W-}$, wherein m is an integer of 0 to 4, and W is
selected from the group consisting of $-\text{C(O)NH-}$, $-\text{S(O)}_2\text{NH-}$,
etc.;

Ar is optionally substituted arylene which is optionally fused to
an aryl, heteroaryl ring, etc.;

30 Y^1 is a chemical bond or a straight- or branched-chain saturated
alkylene, wherein said alkylene is optionally substituted;
and

Z is selected from the group consisting of anilinyll, pyridyl,
thiadiazolyl and $-\text{O-M}$, wherein M is H or a pharmaceutically
35 acceptable cation.

WO 0222577 discloses the following hydroxamate compound as a deacetylase inhibitor:



wherein

- 5 R_1 is H, halo, or a straight chain C_1 - C_6 alkyl;
 R_2 is selected from H, C_1 - C_{10} alkyl, C_4 - C_9 cycloalkyl, C_4 - C_9 heterocycloalkyl, C_4 - C_9 heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, etc.;
 R_3 and R_4 are the same or different and independently H, C_1 - C_6
 10 alkyl, acyl or acylamino, or R_3 and R_4 together with the carbon to which they are bound to represent $C=O$, $C=S$, etc., or R_2 together with the nitrogen to which it is bound and R_3 together with the carbon to which it is bound to form a C_4 - C_9 heterocycloalkyl, a heteroaryl, a polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl
 15 polyheterocycle ring;
 R_5 is selected from H, C_1 - C_6 alkyl, etc.;
 n , n_1 , n_2 and n_3 are the same or different and independently selected from 0-6, when n_1 is 1-6, each carbon atom can be
 20 optionally and independently substituted with R_3 and/or R_4 ;
 X and Y are the same or different and independently selected from H, halo, C_1 - C_4 alkyl, etc.;
 or a pharmaceutically acceptable salt thereof.

SUMMARY OF THE INVENTION

25 The present invention relates to a novel compound, which is useful as a medicament, and to a pharmaceutical composition comprising the same.

More particularly, the present invention relates to a compound, which has a potent inhibitory effect on the activity of
 30 histone deacetylase.

The inventors of the present invention have found that a

histone deacetylase inhibitor, such as compound of the formula
(I) (hereinafter also referred to as compound [I]), has a potent
immunosuppressive effect and potent antitumor effect. Therefore,
a histone deacetylase inhibitor such as compound [I] is useful as
5 an active ingredient of an immunosuppressant and an antitumor
agent, and useful as a therapeutic or prophylactic agent for
diseases such as inflammatory disorders, diabetes, diabetic
complications, homozygous thalassemia, fibrosis, cirrhosis, acute
promyelocytic leukaemia (APL), organ transplant rejections,
10 autoimmune diseases, protozoal infections, tumors, etc.


Accordingly, one object of the present invention is to
provide a compound, which has biological activities for treating
or preventing the diseases as stated above.

Another object of the present invention is to provide a
15 pharmaceutical composition containing the compound [I] as an
active ingredient.

A further object of the present invention is to provide use
of the histone deacetylase inhibitors, such as the compound [I],
for treating or preventing the diseases as stated above.

20 A yet further object of the present invention is to provide
a commercial package comprising the pharmaceutical composition
containing the compound [I] and a written matter associated
therewith, the written matter stating that the pharmaceutical
composition may or should be used for treating or preventing the
25 diseases as stated above.

Namely, the present invention provides
[I] a compound of the formula (I):







wherein



30 R^1 is lower alkyl optionally substituted with one or more
suitable substituent(s);
aryl optionally substituted with one or more suitable

- substituent(s); or
fused ring,
R² is acylamino or optionally protected hydroxy,
L¹ is lower alkenylene, and
5 R³ is hydroxyamino,
or a salt thereof;
[2] the compound of the above-mentioned [1], wherein
R¹ is lower alkyl optionally substituted with
aryl(lower)alkoxyaryl;
10 aryl optionally substituted with the group(s) selected from
lower alkoxy, halogen, aryl, aryl(lower)alkoxy and mono- or
di-substituted amino; or
fused ring, and
R² is acylamino selected from lower alkylcarbonylamino, lower
15 alkylsulfonylamino and arylcarbonylamino; or
hydroxy optionally protected with lower alkyl,
or a salt thereof, etc.



- The compound [I] or a salt thereof can be prepared by the
20 process as illustrated in the following reaction schemes.

Process A









(A-5)








(A-6)













(A-7)









[II-1]

Process B

Process C

Process D

Process E

Process F

wherein

R¹ and R³ are each as defined above,

R⁴ is lower alkyl (e.g., methyl, ethyl, etc.) or aryl (e.g., phenyl, etc.),

R⁵ is lower alkyl (e.g., methyl, ethyl, etc.), aryl (e.g., phenyl, etc.),

R⁶ is hydroxy protecting group (e.g., methyl, etc.),

X is halogen (e.g., iodine, etc.), methanesulfonyloxy, p-toluenesulfonyloxy, etc., and

R^a is hydroxy protecting group (e.g., tetrahydropyranyl, etc.).



In the above-mentioned Processes A, B, C, D, E and F, the compounds [II-1], [II-2], [II-3] and [II-4] are also encompassed in the scope of the compound [II].

In the above-mentioned Processes A, B, C, D, E and F, each of the starting compounds can be prepared, for example, according to the procedures as illustrated in Preparations in the present

specification or in a manner similar thereto. For example, the compounds (A-1), (A-2), (A-3), (A-4), (A-5), (A-6) and (A-7) can be obtained by the procedures as illustrated in Preparations 1, 2, 3, 4, 5, 6 and 7, respectively; the compounds (B-1), (B-2), (B-3) and (B-4) can be obtained by the procedures as illustrated in Preparations 9, 10, 11 and 12, respectively; the compounds (C-1), (C-2), (C-3) and (C-4) can be obtained by the procedures as illustrated in Preparations 14, 15, 16 and 17, respectively; the compounds (D-1), (D-2), (D-3) and (D-4) can be obtained by the procedures as illustrated in Preparations 34, 35, 36 and 37, respectively; the compounds (E-1), (E-2), (E-3) and (E-4) can be obtained by the procedures as illustrated in Preparations 79, 80, 81 and 82, respectively; and the compounds (F-1) and (F-2) can be obtained by the procedures as illustrated in Preparations 84 and 85, respectively. The compound [II-1] can be obtained by the procedure as illustrated in Preparation 8, 13 or 18, and the compounds [II-2], [II-3] and [II-4] can be obtained by the procedures as illustrated in Preparations 38, 83 and 86, respectively.

The compound [I] of the present invention can be obtained from compound [II] according to the following process.

Preparation of the compound [I]



25

wherein

R¹, R², R³, L¹ and R^a are as defined above.

The Compound [I] is obtained by deprotecting the hydroxy group of the Compound [II].

The reaction may be carried out in the presence of acid, for example, hydrogen chloride solution (e.g., hydrogen chloride
5 in solvent such as methanol, dioxane, ethyl acetate, diethyl ether, etc.), acetic acid, p-toluenesulfonic acid, boric acid, etc.

Optionally, one or more suitable solvent(s) for the deprotection is(are) used. Such solvent includes methanol,
10 ethanol, ethyl acetate, dioxane, diethyl ether, acetic acid, etc.

The temperature of the reaction is not critical and the reaction is usually carried out under from cooling to heating.

This process is exemplified by Example 1, etc.

When the compound [I] has stereoisomers, such isomers are
15 also encompassed in the present invention.

The compound [I] may form a salt, which is also encompassed in the present invention. For example, when a basic group such as an amino group is present in a molecule, the salt is exemplified by an acid addition salt (e.g., salt with an
20 inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid,, etc., salt with an organic acid such as methanesulfonic acid, fumaric acid, maleic acid, mandelic acid, citric acid, salicylic acid, etc.), and when an acidic group such as carboxyl group is present, the salt is exemplified by a basic
25 salt (e.g., salt with a metal such as sodium, potassium, calcium, magnesium, aluminum, etc., salt with an amino acid such as lysine, etc.), etc.

In addition, solvates of the compound [I] such as hydrate, ethanolate, etc., are also encompassed in the present invention.

30 Suitable examples and illustration of the various definitions in the above and subsequent descriptions, which the present invention intends to include within its scope, are explained in detail as follows:

The term "halogen" includes fluorine, chlorine, bromine,
35 and iodine.

The term "lower" used in the description is intended to mean 1 to 6 carbon atoms, unless otherwise indicated.

Suitable example of "one or more" means the number of 1 to 6, preferably 1 to 3.

5 Suitable examples of the "lower alkyl" include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, neopentyl, hexyl, isohexyl, etc. Suitable lower alkyl for the "lower alkyl optionally substituted with one or
10 more suitable substituent(s)" for R¹ includes methyl, etc.

 Suitable examples of the "lower alkoxy" include straight or branched one having 1 to 6 carbon atom(s), such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, tert-pentyloxy, neopentyloxy, hexyloxy,
15 isohexyloxy, etc.

 Suitable examples of the "aryl" include a C₆-C₁₆ aryl such as phenyl, naphthyl, anthryl, pyrenyl, phenanthryl, azulenyl, etc. Suitable examples of the "aryl" for the "aryl optionally substituted with one or more suitable substituent(s)" for R¹
20 include phenyl, etc.

 Suitable examples of the "fused ring" include a 5- or 6-membered fused ring, each of which may contain one or more heteroatom selected from a sulfur atom, an oxygen atom and a nitrogen atom besides carbon atoms and one or more carbon atom(s)
25 is/are optionally replaced with oxo group(s). Suitable examples of the "fused ring" include indolyl, isoindolyl, indoliziny, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, quinoxaliny, imidazopyridyl (e.g., imidazo[4,5-c]pyridyl, etc.), tetrahydroimidazopyridyl (e.g., 4,5,6,7-tetrahydro[4,5-c]pyridyl,
30 etc.), 7-azabicyclo[2.2.1]heptyl, 3-azabicyclo[3.2.2]nonanyl, benzoxazolyl, benzodioxolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzothienyl, benzodithiiny, benzoxathiiny, etc. Suitable examples of the "fused ring" for R¹ include 1,3-benzodioxol-5-yl, etc.

35 Suitable examples of the "acyl" for the "acylamino" include

- alkanoyl [e.g., formyl, lower alkyl-carbonyl (e.g., acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, pivaloyl, 2,2-dimethylpropanoyl, hexanoyl, etc.), heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.];
- alkoxycarbonyl [e.g., lower alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl, pentyloxycarbonyl, etc.), etc.];
- lower alkyl-carbonyloxy(lower)alkylcarbonyl (e.g., acetyloxyacetyl, ethylcarbonyloxyacetyl, etc.);
- arylcarbonyl [e.g., C₆₋₁₀ arylcarbonyl (e.g., benzoyl, toluoyl, naphthoyl, fluorenylcarbonyl, etc.)];
- arylalkanoyl [e.g., phenyl(lower)alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl(lower)alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.), etc.];
- arylalkenoyl [e.g., aryl(C₃-C₆)alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl, phenylhexenoyl, etc.), etc.];
- naphthylalkenoyl [e.g., naphthyl(C₃-C₆)alkenoyl (e.g., naphthylpropenoyl, naphthylbutenoyl, naphthylmethacryloyl, naphthylpentenoyl, naphthylhexenoyl, etc.), etc.];
- arylalkoxycarbonyl [e.g., aryl(lower)alkoxycarbonyl such as phenyl(lower)alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), fluorenyl(lower)alkoxycarbonyl (e.g., fluorenylmethyloxycarbonyl, etc.), etc.];
- aryloxycarbonyl (e.g., phenoxycarbonyl, naphthyloxycarbonyl, etc.);
- aryloxyalkanoyl [e.g., aryloxy(lower)alkanoyl (e.g., phenoxyacetyl, phenoxypropionyl, etc.), etc.];
- heterocyclic acyl (e.g., heterocycliccarbonyl, etc.);
- heterocyclic alkanoyl [e.g., heterocyclic(lower)alkanoyl (e.g.,

- heterocyclic acetyl, heterocyclic propanoyl, heterocyclic butanoyl, heterocyclic pentanoyl, heterocyclic hexanoyl, etc.), etc.]; heterocyclic alkenoyl [e.g., heterocyclic(lower)alkenoyl (e.g., heterocyclic propenoyl, heterocyclic butenoyl, heterocyclic pentenoyl, heterocyclic hexenoyl, etc.)]; carbamoyl; alkylcarbamoyl [e.g., lower alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, etc.)]; alkoxy-carbamoyl [e.g., lower alkoxy-carbamoyl (e.g., methoxy-carbamoyl, ethoxy-carbamoyl, etc.)], etc.; arylcarbamoyl [e.g., C₆₋₁₀ arylcarbamoyl (e.g., phenylcarbamoyl, naphthylcarbamoyl, etc.), etc.]; arylthiocarbamoyl [e.g., C₆₋₁₀ arylthiocarbamoyl (e.g., phenylthiocarbamoyl, naphthylthiocarbamoyl, etc.), etc.]; alkylsulfonyl [e.g., lower alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, etc.)]; alkoxy-sulfonyl [e.g., lower alkoxy-sulfonyl (e.g., methoxy-sulfonyl, ethoxy-sulfonyl, etc.)], etc.; arylsulfonyl (e.g., phenylsulfonyl, etc.); arylglyoxyloyl [e.g., C₆₋₁₀ arylglyoxyloyl (e.g., phenylglyoxyloyl, naphthylglyoxyloyl, etc.), etc.]; heterocyclicglyoxyloyl, etc. Each of the acyl is optionally substituted by one or more suitable substituent(s).

- Suitable examples of hydroxy protective group for the "optionally protected hydroxy" for R² include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, etc.); lower alkoxy(lower)alkyl (e.g., methoxymethyl, etc.); lower alkoxy(lower)alkoxy(lower)alkyl (e.g., 2-methoxyethoxymethyl, etc.); aryl(lower)alkyl in which the aryl portion is optionally substituted with one or more suitable substituent(s) (e.g., benzyl (Bn), p-methoxybenzyl, 2,3-dimethoxybenzyl, etc.); aryl(lower)alkoxy(lower)alkyl in which the aryl portion is optionally substituted with one or more suitable substituent(s)

(e.g., benzyloxymethyl, p-methoxybenzyloxymethyl, etc.);
lower alkylthio(lower)alkyl (e.g., methylthiomethyl,
ethylthiomethyl, propylthiomethyl, isopropylthiomethyl,
butylthiomethyl, isobutylthiomethyl, hexylthiomethyl, etc.);
5 heterocyclic group (e.g., tetrahydropyranyl, etc.);
trisubstituted silyl [e.g., tri(lower)alkylsilyl (e.g.,
trimethylsilyl, triethylsilyl, tributylsilyl, tert-
butyldimethylsilyl (TBDMS), tri-tert-butylysilyl, etc.), lower
alkyldiarylsilyl (e.g., methyldiphenylsilyl, ethyldiphenylsilyl,
10 propyldiphenylsilyl, tert-butyldiphenylsilyl (TBDPS), etc.),
etc.];
acyl as described above;
lower alkenyl (e.g., vinyl, allyl, etc.), etc.

Suitable examples of the "lower alkenylene" include a
15 straight or branched alkenylene having 1 to 6 carbon atom(s),
such as vinylene, 1-methylvinylene, 2-methylvinylene, 1-
propenylene, 2-propenylene, 2-methyl-1-propenylene, 2-methyl-2-
propenylene, 1-butenylene, 2-butenylene, 3-butenylene, 1-
pentenylene, 2-pentenylene, 3-pentenylene, 4-pentenylene, 1-
20 hexenylene, 2-hexenylene, 3-hexenylene, 4-hexenylene, 5-
hexenylene, etc. Suitable examples of the "lower alkenylene" for
L¹ include vinylene, etc.

Suitable examples of R¹ for the compound [I] include
lower alkyl optionally substituted with aryl(lower)alkoxyaryl
25 (e.g., 4-benzyloxyphenyl, etc.), of which the preferred are
methyl, (4-benzyloxyphenyl)methyl, etc.;
aryl optionally substituted with the group(s) selected from lower
alkoxy (e.g., methoxy, ethoxy, propoxy, etc.), halogen (e.g.,
chloro, bromo, iodo, etc.), aryl (e.g., phenyl, naphthyl, etc.),
30 aryl(lower)alkoxy (e.g., benzyloxy, naphthylmethyloxy, etc.) and
mono- or di-substituted amino (e.g., methylamino, ethylamino,
N,N-dimethylamino, etc.), of which the preferred are chlorophenyl,
ethoxyphenyl, benzyloxyphenyl, biphenyl, N,N-
dimethylaminophenyl, etc.; and
35 fused ring (e.g., benzodioxolyl, etc.), of which the preferred

are 1,3-benzodioxol-5-yl, etc., etc.

Suitable examples of "acylamino" for R² include lower alkyl-carbonylamino (e.g., acetylamino, ethylcarbonylamino, propylcarbonylamino, etc.), lower alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, etc.), arylcarbonylamino (e.g., phenylcarbonylamino, naphthylcarbonylamino, etc.), etc., of which the preferred are acetylamino, methylsulfonylamino, phenylcarbonylamino, etc.

Suitable examples of "optionally protected hydroxy" include hydroxy, lower alkoxy (e.g., methoxy, ethoxy, propoxy, etc.), of which the preferred are hydroxy, methoxy, etc.

The following abbreviations are also used in the present specification: Boc (t-butyloxycarbonyl); HOBT (1-hydroxybenzotriazole); WSCD (1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide); DMF (N,N-dimethylformamide); aq. (aqueous solution); Me (methyl); MeOH (methanol); Et (ethyl); EtOH (ethanol); tBu (t-butyl); t-Boc (t-butoxycarbonyl); TsCl (p-toluenesulfonyl chloride); Ac (acetyl); AcOH (acetic acid); Ph (phenyl); DIEA (diisopropylethylamine); Bn (benzyl); Bz (benzoyl); TBAI (tetrabutylammonium iodide); TBAF (tetrabutylammonium fluoride); CAN (cerium ammonium nitrate); THP (tetrahydropyranyl); IPE (diisopropylether).

Test Method

In order to show the usefulness of the compound [I] of the invention, the pharmacological test result of the representative compound of the present invention is shown in the following.

Test 1: Determination of histone deacetylase inhibitory activity

The partial purification of human histone deacetylase, the preparation of [³H] acetyl histones, and the assay for histone deacetylase activity were performed as follows basically according to the method as proposed by Yoshida et al.

Partial purification of human histone deacetylase

The human histone deacetylase was partially purified from human T cell leukemia Jurkat cells. Jurkat cells (5 × 10⁸ cells) were suspended in 40 mL of the HDA buffer consisting of 15 mM

potassium phosphate (pH 7.5), 5% glycerol and 0.2 mM EDTA. After homogenization, nuclei were collected by centrifugation (35,000 × g, 10 min) and homogenized in 20 mL of the same buffer supplemented with 1 M (NH₄)₂SO₄. The viscous homogenate was
5 sonicated and clarified by centrifugation (35,000 × g, 10 min), and the deacetylase was precipitated by raising the concentration of (NH₄)₂SO₄ to 3.5 M. The precipitated protein was dissolved in 10 mL of the HDA buffer and dialyzed against 4 liters of the same buffer. The dialyzate was then loaded onto a DEAE-cellulose
10 (Whatman DE52) column (25 × 85 mm) equilibrated with the same buffer and eluted with 300 mL of a linear gradient (0-0.6 M) of NaCl. A single peak of histone deacetylase activity appeared between 0.3 and 0.4 M NaCl.

Preparation of [³H] acetyl histone

15 To obtain [³H] acetyl-labeled histone as the substrate for the histone deacetylase assay, 1 × 10⁸ cells of Jurkat in 20 mL of RPMI-1640 medium (supplemented with 10% FBS, penicillin (50 units/mL) and streptomycin (50 µg/mL)) were incubated with 300 MBq [³H] sodium acetate in the presence of 5 mM sodium butyrate
20 for 30 min in 5% CO₂-95% air atmosphere at 37°C in a 75 cm² flask, harvested into a centrifuge tube (50 mL), collected by centrifugation at 1000 rpm for 10 min, and washed once with phosphate-buffered saline. The washed cells were suspended in 15 mL of ice-cold lysis buffer (pH 6.5, 10 mM Tris-HCl, 50 mM sodium
25 bisulfite, 1% Triton X-100, 10 mM MgCl₂, 8.6% sucrose). After Dounce homogenization (30 stroke), the nuclei were collected by centrifugation at 1000 rpm for 10 min, washed 3 times with 15 mL of the lysis buffer, and once with 15 mL of ice-cooled washing buffer (pH 7.4, 10 mM Tris-HCl, 13 mM EDTA) successively. The
30 pellet was suspended in 6 mL of ice-cooled water using a mixer, and 68 µl of H₂SO₄ was added to the suspension to give a concentration of 0.4 N. After incubation at 4°C for 1 hr, the suspension was centrifuged for 5 min at 15,000 rpm, and the supernatant was taken and mixed with 60 mL of acetone. After
35 overnight incubation at -20°C, the coagulated material was

collected by microcentrifugation, air-dried, and stored at -80°C.

Assay for histone deacetylase activity

For the standard assay, 10 µl of [³H] acetyl-labeled histones were added to 90 µl of the enzyme fraction, and the mixture was incubated at 25°C for 30 min. The reaction was stopped by addition of 10 µl of HCl. The released [³H] acetic acid was extracted with 1 mL of ethyl acetate, and 0.9 mL of the solvent layer was taken into 10 mL of toluene scintillation solution for determination of radioactivity.

10 Test 2: Determination of T-cell growth inhibitor activity

The T lymphocyte blastogenesis test was performed in microtiter plates with each well containing 1.5×10^5 splenic cells of Lewis rats in 0.1 mL RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 50 mM 2-mercaptoethanol, penicillin (100 units/mL) and streptomycin (100 µg/mL), to which Concanavalin A (1 µg/mL) was added. The cells were incubated at 37°C in a humidified atmosphere of 5% CO₂ for 72 hrs. After the culture period, suppressive activities of the test compounds in T lymphocyte blastogenesis were quantified by AlamarBlue (trademark) Assay. The test samples were dissolved in DMSO and further diluted with RPMI-1640 medium and added to the culture. The activities of the test compounds were expressed as IC₅₀.

The results of those tests are shown in the Table 1.

Table 1: HDAC inhibitory activity and T-cell growth inhibitory activity of the compound of the present invention

Examples	Test 1:	Test 2:
	HDAC inhibitory activity IC ₅₀ (nM)	T-cell growth inhibitory activity IC ₅₀ (nM)
Compound 2	<200	<2000
Compound 10	<200	<2000
Compound 13	<200	<2000
Compound 14	<200	<2000

The pharmaceutical composition of the present invention comprising histone deacetylase inhibitor such as the compound [I] is useful as a therapeutic or prophylactic agent for diseases caused by abnormal gene expression, such as inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), protozoal infection, etc. Further, it is useful as an antitumor agent or immunosuppressant, which prevents an organ transplant rejection and autoimmune diseases as exemplified below.

Rejection reactions by transplantation of organs or tissues (e.g., heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, limb, muscle, nerve, intervertebral disc, trachea, myoblast, cartilage, etc.), etc.; graft-versus-host reactions following bone marrow transplantation; autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, etc.); infections caused by pathogenic microorganisms (e.g., *Aspergillus fumigatus*, *Fusarium oxysporum*, *Trichophyton asteroides*, etc.), etc.

Furthermore, pharmaceutical preparations of the histone

deacetylase inhibitor, such as the compound [I], are useful for the therapy or prophylaxis of the following diseases.

- Inflammatory or hyperproliferative skin diseases or cutaneous manifestations of immunologically-mediated diseases
- 5 (e.g., psoriasis, atopic dermatitis, contact dermatitis, eczematoid dermatitis, seborrheic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, erythema, dermal eosinophilia, lupus erythematosus, acne, alopecia areata, etc.);
- 10 autoimmune diseases of eye (e.g., keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical keratitis, corneal epithelial dystrophy, keratoleukoma, ocular pemphigus, Mooren's ulcer, scleritis, Grave's ophthalmopathy, Vogt-Koyanagi-Harada
- 15 syndrome, keratoconjunctivitis sicca (dry eye), phlyctenule, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, etc.); reversible obstructive airway diseases [e.g., asthma (e.g., bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, and dust asthma), particularly chronic or inveterate
- 20 asthma (e.g., late asthma, airway hyper-responsiveness, etc.), bronchitis, etc.];
- mucosal or vascular inflammations (e.g., gastric ulcer, ischemic or thrombotic vascular injury, ischemic bowel diseases, enteritis, necrotizing enterocolitis, intestinal damages associated with
- 25 thermal burns, leukotriene B₄-mediated diseases, etc.); intestinal inflammations/allergies (e.g., coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, etc.);
- food-related allergic diseases with symptomatic manifestation
- 30 remote from the gastrointestinal tract (e.g., migraine, rhinitis, eczema, etc.);
- renal diseases (e.g., interstitial nephritis, Goodpasture's syndrome, hemolytic uremic syndrome, diabetic nephropathy, etc.);
- nervous diseases (e.g., multiple myositis, Guillain-Barre
- 35 syndrome, Meniere's disease, multiple neuritis, solitary neuritis,

- cerebral infarction, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), radiculopathy, etc.); cerebral ischemic diseases [e.g., head injury, hemorrhage in brain (e.g., subarachnoid hemorrhage, intracerebral hemorrhage, etc.), cerebral thrombosis, cerebral embolism, cardiac arrest, 5 stroke, transient ischemic attack (TIA), hypertensive encephalopathy, etc.]; endocrine diseases (e.g., hyperthyroidism, Basedow's disease, etc.);
- 10 hematic diseases (e.g., pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, etc.); bone diseases (e.g., osteoporosis, etc.);
- 15 respiratory diseases (e.g., sarcoidosis, pulmonary fibrosis, idiopathic interstitial pneumonia, etc.); skin diseases (e.g., dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photosensitivity, cutaneous T-cell lymphoma, etc.);
- 20 circulatory diseases (e.g., arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocardosis, etc.); collagen diseases (e.g., scleroderma, Wegener's granuloma, Sjögren's syndrome, etc.); adiposis;
- 25 eosinophilic fasciitis; periodontal diseases (e.g., damage to gingiva, periodontium, alveolar bone or substantia ossea dentis, etc.); nephrotic syndrome (e.g., glomerulonephritis, etc.); male pattern alopecia, alopecia senile;
- 30 muscular dystrophy; pyoderma and Sezary syndrome; chromosome abnormality-associated diseases (e.g., Down's syndrome, etc.); Addison's disease;
- 35 active oxygen-mediated diseases (e.g., organ injury [e.g.,

ischemic circulation disorders of organs (e.g., heart, liver, kidney, digestive tract, etc.) associated with preservation and transplantation, etc.], ischemic diseases (e.g., thrombosis, cardiac infarction, etc.), intestinal diseases (e.g., endotoxin shock, pseudomembranous colitis, drug- or radiation-induced colitis, etc.), renal diseases (e.g., ischemic acute renal insufficiency, chronic renal failure, etc.), pulmonary diseases [e.g., toxicosis caused by pulmonary oxygen or drugs (e.g., paracort, bleomycin, etc.), lung cancer, pulmonary emphysema, etc.], ocular diseases (e.g., cataracta, iron-storage disease (siderosis bulbi), retinitis, pigmentosa, senile plaques, vitreous scarring, corneal alkali burn, etc.), dermatitis (e.g., erythema multiforme, linear immunoglobulin A bullous dermatitis, cement dermatitis, etc.), other diseases [e.g., gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental pollution (e.g., air pollution, etc.), aging, carcinogen, metastasis of carcinoma, hypobaropathy, etc.], etc.]; diseases caused by histamine release or leukotriene C4 release; restenosis of coronary artery following angioplasty and prevention of postsurgical adhesions; autoimmune diseases and inflammatory conditions [e.g., primary mucosal edema, autoimmune atrophic gastritis, premature menopause, male sterility, juvenile diabetes mellitus, pemphigus vulgaris, pemphigoid, sympathetic ophthalmitis, lens-induced uveitis, idiopathic leukopenia, active chronic hepatitis, idiopathic cirrhosis, discoid lupus erythematosus, autoimmune orchitis, arthritis (e.g., arthritis deformans, etc.), polychondritis, etc.]; Human Immunodeficiency Virus (HIV) infection, AIDS; allergic conjunctivitis; hypertrophic cicatrix and keloid due to trauma, burn, surgery, etc., etc.

Therefore, the pharmaceutical composition of the present invention is useful for the therapy and prophylaxis of liver diseases [e.g., immunogenic diseases (e.g., chronic autoimmune

liver diseases such as autoimmune hepatic diseases, primary biliary cirrhosis, sclerosing cholangitis, etc.), partial liver resection, acute liver necrosis (e.g., necrosis caused by toxins, viral hepatitis, shock or anoxia, etc.), hepatitis B, non-A non-B
5 hepatitis, hepatocirrhosis, hepatic failure (e.g., fulminant hepatitis, late-onset hepatitis and "acute-on-chronic" liver failure (acute liver failure on chronic liver diseases), etc.), etc.].

The pharmaceutical composition of the present invention can
10 be used in the form of pharmaceutical preparation, for example, in a solid, semisolid or liquid form, which contains the histone deacetylase inhibitor, such as the compound [I], as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral
15 administrations. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, injections, ointments, liniments, eye drops, lotion, gel, cream, and any other form suitable for use.

20 The carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in a solid, semisolid, or liquid form.
25 Additionally, auxiliary, stabilizing, thickening, solubilizing and coloring agents and perfumes may be used in combination with the carrier.

For application to human, the composition is preferably applied by intravenous, intramuscular, topical or oral
30 administration, or by a vascular stent impregnated with the compound [I]. While the dosage of therapeutically effective amount of the histone deacetylase inhibitor, such as the compound [I], varies depending upon the age and condition of each individual patient to be treated, when an individual patient is
35 to be treated, in the case of intravenous administration, a daily

dose of 0.01-10 mg of the histone deacetylase inhibitor, such as the compound [I], per kg weight of human being, in the case of intramuscular administration, a daily dose of 0.1-10 mg of the histone deacetylase inhibitor, such as the compound of the
5 formula [I], per kg body weight of human being, and in the case of oral administration, a daily dose of 0.5-50 mg of the histone deacetylase inhibitor, such as the compound [I], per kg body weight of human being, is generally given for treatment.

During the preparation of the above-mentioned
10 pharmaceutical administration forms, the compound [I] or a salt thereof can be also combined together with other immunosuppressive substances, such as repamycin, mycophenolic acid, cyclosporin A, tacrolimus and brequinar sodium.

Hereinafter the reactions in respective Preparations and
15 Examples for preparing the compound [I] of the present invention are explained in more detail. The invention should not be restricted by the following Preparations and Examples in any way.

Preparation 1

To magnesium turning (985 mg) was dropwisely added a
20 solution of 4-bromobenzaldehyde diethyl acetal (10 g) in tetrahydrofuran (100 mL) under nitrogen atmosphere. The reaction mixture was stirred at ambient temperature until the magnesium disappeared (for 1 hr). The resulting Grignard's reagent was added dropwise at 0°C to a mixture of 4-(dimethylamino)benzoyl
25 chloride (7.08 g) and bis(triphenylphosphine)nickel(II) chloride (75.7 mg) in tetrahydrofuran (100 mL) with stirring, and the mixture was allowed to warm to ambient temperature and stirred for 2 hrs. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was stirred for 30
30 min. The reaction mixture was extracted with ethyl acetate, and the organic phase was washed sequentially with saturated aqueous ammonium chloride solution, saturated aqueous sodium hydrogen carbonate solution and brine. The organic phase was dried over sodium sulfate, and the solvent was evaporated in vacuo. The
35 residue was purified by silica gel column chromatography (eluting

with chloroform and methanol (95:5)) to give Compound (1) as brown oil (10.5 g).

¹H-NMR (300 MHz, CDCl₃, δ): 1.26 (6H, t, J=7.4 Hz), 3.08 (6H, s), 3.61 (4H, m), 5.57 (1H, s), 6.68 (2H, d, J=8.1 Hz), 7.56 (2H, d, J=8.4 Hz), 7.72 (2H, d, J=8.1 Hz), 7.89 (2H, d, J=8.4 Hz).

Preparation 2

To a stirred solution of Compound (1) (10.5 g) in ethanol (80 mL) were added hydroxylamine hydrochloride (8.91 g) and pyridine (77.8 mL). The reaction mixture was stirred at ambient temperature for 14 hrs, followed by addition of hydroxylamine hydrochloride (8.91 g) and additional stirring for 3 hrs. The reaction mixture was poured into 300 mL of saturated aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The organic phase was sequentially washed with saturated aqueous ammonium chloride solution and brine, and dried over sodium sulfate. The solvent was removed in vacuo, and the residue was purified by silica gel column chromatography (eluting with chloroform and methanol (95:5)). The resulting solid was triturated with diisopropyl ether:hexane = 1:1 to give Compound (2) as a pale yellow powder (4.89 g). The (E) and (Z) mixture was used in the next reaction.

Preparation 3

To a suspension of Compound (2) (4.89 g), zinc powder (4.67 g) and ammonium acetate (1.1 g) in ethanol (50 mL) was added aqueous ammonia (28%, 38.2 mL), and the mixture was refluxed for 1 hr. The resulting zinc was filtered off and the organic solvent was removed in vacuo. The residue was extracted with ethyl acetate. The organic phase was sequentially washed with saturated aqueous sodium hydrogen carbonate solution, water, and brine, and dried over sodium sulfate. The solvent was removed in vacuo to give Compound (3) as yellow oil (4.57 g).

¹H-NMR (300 MHz, CDCl₃, δ): 1.22 (6H, t, J=7.0 Hz), 2.91 (6H, s), 3.52 (2H, m), 3.60 (2H, m), 5.14 (1H, s), 5.46 (1H, s), 6.68 (2H, d, J=8.7 Hz), 7.20 (2H, d, J=9.1 Hz), 7.36 (2H, d, J=8.4 Hz), 7.40 (2H, d, J=8.4 Hz);

MASS (ES+): m/e 312 (M-NH₂).

Preparation 4

To a stirred solution of Compound (3) (2.6 g) in dichloromethane (25 mL) were added acetic anhydride (0.822 mL) and pyridine (0.704 mL). The reaction mixture was stirred at ambient temperature for 3 hrs. The solvent was removed in vacuo. The residue was extracted with ethyl acetate and washed with saturated ammonium chloride solution, saturated sodium hydrogen carbonate solution and brine. The organic phase was dried over sodium sulfate, and the solvent was removed in vacuo. The resulting yellow oil was purified by silica gel column chromatography eluted with chloroform: methanol=95: 5 to give Compound (4) as yellow oil (2.48 g).

¹H-NMR (300 MHz, CDCl₃, δ): 1.23 (6H, t, J=7.2 Hz), 2.05 (3H, s), 2.93 (6H, s), 3.53 (2H, m), 3.61 (2H, m), 5.47 (1H, s), 5.95 (1H, d, J=7.2 Hz), 6.16 (1H, d, J=7.2 Hz), 6.66 (2H, d, J=8.4 Hz), 7.06 (2H, d, J=8.8 Hz), 7.23 (2H, d, J=8.1 Hz), 7.41 (2H, d, J=8.0 Hz);

MASS (ES+): m/e 371 (M+1).

Preparation 5

To a solution of Compound (4) (2.48 g) in tetrahydrofuran (25 mL) was added 5% v/v sulfuric acid (10 mL), and the mixture was stirred for 30 min. The pH value of the mixture was adjusted to 8 with 1N sodium hydroxide. The mixture was extracted with ethyl acetate, and the organic phase was washed with saturated aqueous sodium hydrogen carbonate solution, water and brine, and dried over sodium sulfate. The solvent was removed in vacuo, and the residue was triturated with diisopropyl ether to give Compound (5) as a pale yellow powder (1.66 g).

¹H-NMR (300 MHz, CDCl₃, δ): 2.09 (3H, s), 2.95 (3H, s), 6.00 (1H, d, J=7.0 Hz), 6.18 (1H, d, J=7.3 Hz), 6.68 (2H, d, J=8.8 Hz), 7.05 (2H, d, J=8.5 Hz), 7.44 (2H, d, J=8.0 Hz), 7.85 (2H, d, J=7.6 Hz), 10.0 (1H, s);

MASS (ES+): m/e 297 (M+1).

Preparation 6

To a suspension of Compound (5) (1.6 g) in toluene (16 mL) was added ethyl (triphenylphosphoranylidene)acetate (2.07 g), and the mixture was heated at 70°C for 30 min. Additional ethyl (triphenylphosphoranylidene)acetate (690 mg) was added thereto, and the mixture was heated for 30 min. The solvent was removed in vacuo to give Compound (6), which was used in the next reaction without further purification.

¹H-NMR (300 MHz, CDCl₃, δ): 1.34 (3H, t, J=7.1 Hz), 2.07 (3H, s), 2.94 (6H, s), 4.26 (2H, q, J=7.1 Hz), 5.98 (1H, d, J=7.6 Hz), 6.14 (1H, d, J=16.2 Hz), 6.67 (1H, d, J=8.8 Hz), 7.06 (1H, d, J=8.4 Hz);

MASS (ES⁺): m/e 367 (M+1).

Preparation 7

To a solution of Compound (6) (1.98 g, as a mixture with triphenylphosphine oxide) in dioxane (20 mL) was added 1N lithium hydroxide (21.6 mL), and the mixture was stirred at ambient temperature for 14 hrs. The mixture was acidified with 1N hydrochloric acid to pH 4 and extracted with ethyl acetate. The organic phase was washed with brine, dried over sodium sulfate, and the solvent was removed in vacuo. The resulting brown form was triturated with diisopropyl ether to give Compound (7) as a colorless powder (1.73 g).

¹H-NMR (300 MHz, CDCl₃, δ): 2.06 (3H, s), 2.93 (6H, s), 6.12 (1H, m), 6.9 (1H, d, J=16.0 Hz), 6.49 (1H, br), 6.68 (2H, d, J=8.7 Hz), 7.05 (2H, d, J=8.8 Hz), 7.27 (2H, d, J=8.0 Hz), 7.48 (2H, d, J=8.4 Hz), 7.67 (1H, d, J=16.0 Hz):

MASS (ES⁺): m/e 339 (M+1).

Preparation 8

To a stirred solution of Compound (7) (1.73 g) in N,N-dimethylformamide (17 mL) were added 1-hydroxybenzotriazole (HOBT, 898 mg), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (WSCD, 1.03 g) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (659 mg), and the mixture was stirred for 90 min. Additional HOBT (499 mg), WSCD (502 mg) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (330

- mg) were added thereto, and the mixture was stirred for 30 min. The mixture was poured into water and extracted with ethyl acetate. The organic phase was sequentially washed with saturated aqueous ammonium chloride solution, sodium hydrogen carbonate solution and brine. The organic phase was dried over sodium sulfate and concentrated in vacuo. The resulting pale yellow form was triturated with diisopropyl ether to give Compound (8) as a pale yellow powder (2.09 g). The obtained Compound (8) was used in Example 1.
- ¹H-NMR (300 MHz, CDCl₃, δ): 1.63 (3H, br), 1.85 (3H, br), 2.06 (3H, s), 2.93 (6H, s), 3.65 (1H, br), 3.97 (1H, br), 5.01 (1H, br), 6.06 (1H, d, J=7.7 Hz), 6.13 (1H, d, J=7.4 Hz), 6.67 (2H, d, J=8.8 Hz), 6.85 (1H, br), 7.05 (2H, d, J=8.9 Hz), 7.24 (2H, d, J=8.0 Hz), 7.44 (2H, d, J=7.7 Hz), 7.67 (1H, br.d, J=15.9 Hz);
- MASS (ES⁺): m/e 438 (M+1).

Preparation 9

- To a stirred solution of Compound (3) (2 g) in N,N-dimethylformamide were added HOBT (1.07 g), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (WSCD-HCl, 1.52 g), and benzoic acid (818 mg). The reaction mixture was stirred at ambient temperature for 3 hrs. The resulting mixture was poured into water and extracted with ethyl acetate. The organic phase was sequentially washed with saturated aqueous ammonium chloride solution, saturated aqueous sodium hydrogen carbonate solution and brine. The resulting organic phase was dried over sodium sulfate, and the solvent was removed in vacuo to give Compound (9) as a pale yellow solid (2.6 g).
- ¹H-NMR (300 MHz, CDCl₃, δ): 1.23 (3H, t, J=7.1 Hz), 2.93 (6H, s), 3.52 (2H, m), 5.48 (1H, s), 6.36 (1H, d, J=7.7 Hz), 6.61 (1H, d, J=8.6 Hz), 6.68 (2H, d, J=8.9 Hz), 7.13 (2H, d, J=8.9 Hz), 7.33 (2H, m), 7.45 (3H, m), 7.80 (2H, d, J=8.5 Hz);
- MASS (ES⁺): m/e 433 (M+1).

Preparation 10

- Compound (10) (1.64 g) was obtained in a manner similar to Preparation 5.

^1H -NMR (300 MHz, CDCl_3 , δ): 2.95 (6H, s), 6.36 (1H, d, $J=6.9$ Hz), 6.64 (1H, d, $J=8.0$ Hz), 6.69 (2H, d, $J=8.8$ Hz), 7.11 (2H, d, $J=8.8$ Hz), 7.44 (2H, m), 7.51 (3H, m), 7.84 (4H, m), 9.99 (1H, s);

5 MASS (ES+): m/e 359 (M+1).

Preparation 11

Compound (11) (1.95 g) was obtained in a manner similar to Preparation 6.

^1H -NMR (300 MHz, CDCl_3 , δ): 1.34 (3H, t, $J=7.1$ Hz), 2.94 (6H, s), 10 4.26 (2H, q, $J=7.2$ Hz), 6.33 (1H, d, $J=7.3$ Hz), 6.40 (1H, d, $J=16.0$ Hz), 6.50 (1H, d, $J=6.9$ Hz), 6.69 (2H, d, $J=8.8$ Hz);
MASS (ES+): m/e 429 (M+1).

Preparation 12

Compound (12) (1.79 g) was obtained in a manner similar to
15 Preparation 7.

^1H -NMR (300 MHz, CDCl_3 , δ): 2.95 (6H, s), 6.34 (1H, d, $J=16.0$ Hz), 6.63 (1H, d, $J=7.4$ Hz), 6.71 (2H, d, $J=8.7$ Hz), 7.14 (2H, d, $J=8.5$ Hz), 7.38 (2H, d, $J=8.5$ Hz), 7.38 (2H, d, $J=8.0$ Hz), 7.45 (2H, m), 7.51 (3H, m), 7.75 (1H, d, $J=16.0$ Hz), 7.83 (2H, d, 20 $J=6.6$ Hz);
MASS (ES+): m/e 401 (M+1).

Preparation 13

Compound (13) (1.94 g) was obtained in a manner similar to Preparation 8. The obtained Compound (13) was used in Example 2.

^1H -NMR (300 MHz, CDCl_3 , δ): 1.62 (3H, br), 1.85 (3H, br), 2.95 (6H, s), 3.65 (1H, br), 3.97 (1H, br), 5.01 (1H, br), 6.33 (1H, d, $J=7.8$ Hz), 6.64 (1H, d, $J=6.9$ Hz), 6.70 (2H, d, $J=8.8$ Hz), 7.13 (2H, d, $J=8.8$ Hz), 7.33 (2H, d, $J=8.1$ Hz), 7.46 (5H, m), 7.70 (1H, br, $J=16.0$ Hz), 7.82 (2H, d, $J=8.1$ Hz);
25 MASS (ES+): m/e 500 (M+1).

Preparation 14

To a solution of 1-(3-bromophenyl)ethanone (5.0 g) in ethanol (50 mL) were added hydroxylamine hydrochloride (3.49 g) and pyridine (30.5 mL), and the mixture was stirred at ambient
35 temperature for 1 hr. The organic solvent was removed in vacuo,

and the residue was extracted with ethyl acetate. The organic phase was washed with saturated aqueous ammonium chloride solution and dried over sodium sulfate. The solvent was removed in vacuo to give Compound (14). The resulting crude product was
5 used in the next reaction without further purification.

¹H-NMR (300 MHz, CDCl₃, δ): 2.26 (3H, s), 7.24 (1H, t, J=8.0 Hz), 7.49 (1H, ddd, J=8.0, 1.8, 1.1 Hz), 7.56 (1H, ddd, J=8.0, 1.8, 1.1 Hz), 7.80 (1H, t, J=1.8 Hz).

Preparation 15

10 To a solution of Compound (14) (5.38 g) in ethanol (54 mL) were added zinc powder (8.22 g), ammonium acetate (1.94 g) and aqueous ammonia (28%, 33.6 mL), and the mixture was refluxed for 1 hr. Additional aqueous ammonia (28%, 33.6 mL) was added to the mixture, and the mixture was refluxed for 2 hrs. The mixture was
15 allowed to cool to ambient temperature and concentrated in vacuo. The residue was extracted with ethyl acetate. The organic phase was washed with saturated aqueous sodium hydrogen carbonate solution and brine, and dried over sodium sulfate. The solvent was removed in vacuo to give a mixture of Compound (15) and 1-
20 phenylethylamine (10:7, 3.7 g). The resulting crude product was used in the next reaction without further purification.

¹H-NMR (300 MHz, CDCl₃, δ): 1.38 (3H, d, J=7.0 Hz), 4.10 (1H, q, J=7.0 Hz), 7.19 (1H, t, J=7.7 Hz), 7.34 (1H, m), 7.51 (1H, t, J=1.8 Hz), 7.63 (1H, m).

25 Preparation 16

To a solution of the mixture of Compound (15) and 1-phenylethylamine (10:7, 3.71 g) in N,N-dimethylformamide (37 mL) were added benzoic acid (2.49 g), 1-hydroxybenzotriazole (3.26 g) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride
30 (WSCD-HCl, 4.62 g), and the mixture was stirred for 1 day. The reaction mixture was extracted with ethyl acetate. The organic phase was sequentially washed with water, saturated aqueous ammonium chloride solution, saturated aqueous sodium hydrogen carbonate solution and brine, and dried over sodium sulfate. The
35 solvent was removed in vacuo to give a mixture of Compound (16)

and N-(1-phenylethyl)benzamide (10:7, 2.65 g) as a colorless solid.

¹H-NMR (300 MHz, CDCl₃, δ): 1.58 (3H, d, J=7.0 Hz), 5.31 (1H, q, J=7.0 Hz), 6.34 (1H, br), 7.22 (1H, t, J=7.7 Hz), 7.28-7.54 (6H, m), 7.77 (2H, m).

Preparation 17

To a solution of the mixture of Compound (16) and N-(1-phenylethyl)benzamide (10:7, 2.65 g) in N,N-dimethylformamide (26.5 mL) were added acrylic acid (3.4 mL), palladium(II) acetate (97.8 mg), triphenylphosphine (457 mg) and N,N-diisopropylethylamine (4.55 mL), and the mixture was stirred at 100°C for 3 hrs. The resulting mixture was allowed to cool to ambient temperature and poured into 1N sodium hydroxide solution. The mixture was washed with ether, and the aqueous phase was acidified with 1N hydrogen chloride and extracted with ethyl acetate. The organic phase was washed with saturated aqueous ammonium chloride solution and brine, dried over sodium sulfate, and concentrated in vacuo. The residual yellow solid was triturated with diisopropyl ether to give Compound (17) as a colorless powder (731 mg).

¹H-NMR (300 MHz, CDCl₃/MeOH-d₄, δ): 1.63 (3H, d, J=7.0 Hz), 5.35 (1H, m), 6.44 (1H, d, J=16.0 Hz), 7.37-7.51 (6H, m), 7.55 (1H, s), 7.71 (1H, d, J=16.0 Hz), 7.78 (2H, d, J=7.6 Hz);
MASS (ES⁺): m/e 296 (M+1).

Preparation 18

Compound (18) (970 mg) was obtained in a manner similar to Preparation 8. The obtained Compound (18) was used in Example 3.

¹H-NMR (300 MHz, CDCl₃, δ): 1.62 (3H, d, J=7.0 Hz), 1.53-1.91 (6H, br), 3.66 (1H, m), 3.97 (1H, m), 5.00 (1H, br), 5.35 (1H, m), 6.36 (1H, m), 7.35-7.54 (7H, m), 7.72 (1H, d, J=16.0 Hz), 7.78 (2H, d, J=8.0 Hz);
MASS (ES⁺): m/e 395 (M+1).

Preparation 19

Compound (19) (8.4 g) was obtained in a manner similar to Preparation 1.

^1H -NMR (300 MHz, CDCl_3 , δ): 1.26 (3H, t, $J=7.0$ Hz), 3.61 (4H, m), 5.15 (2H, s), 5.57 (1H, s), 7.04 (2H, d, $J=8.8$ Hz), 7.35–7.46 (5H, m), 7.58 (2H, d, $J=8.5$ Hz), 7.75 (2H, d, $J=8.0$ Hz), 7.82 (2H, d, $J=8.8$ Hz);

5 MASS (ES+): m/e 391 ($M+1$).

Preparation 20

Compound (20) (5.8 g) was obtained in a manner similar to Preparation 2.

Preparation 21

10 Compound (21) (5.7 g) was obtained in a manner similar to Preparation 3.

^1H -NMR (300 MHz, CDCl_3 , δ): 1.22 (3H, t, $J=7.0$ Hz), 1.26 (3H, t, $J=7.0$ Hz), 3.49–3.65 (4H, m), 5.03 (2H, s), 5.17 (1H, s), 5.46 (1H, s), 6.91 (2H, d, $J=8.9$ Hz), 7.27 (2H, d, $J=8.9$ Hz), 7.31–

15 7.43 (9H, m).

Preparation 22

Compound (22) (3.15 g) was obtained in a manner similar to Preparation 4.

20 ^1H -NMR (300 MHz, CDCl_3 , δ): 5.05 (2H, s), 6.08 (1H, d, $J=7.1$ Hz), 6.23 (1H, d, $J=7.5$ Hz), 6.94 (2H, d, $J=8.8$ Hz), 7.11 (2H, d, $J=8.8$ Hz), 7.31–7.43 (7H, m), 7.85 (2H, d, $J=8.4$ Hz), 9.99 (1H, s).

Preparation 23

25 Compound (23) (3.76 g) was obtained in a manner similar to Preparation 6.

Preparation 24

Compound (24) (2.06 g) was obtained in a manner similar to Preparation 7.

30 ^1H -NMR (300 MHz, $\text{DMSO}-d_6$, δ): 2.00 (3H, s), 5.15 (2H, s), 6.13 (1H, d, $J=8.5$ Hz), 6.56 (1H, d, $J=16.1$ Hz), 7.04 (2H, d, $J=8.9$ Hz), 7.25 (2H, d, $J=8.8$ Hz), 7.36 (2H, d, $J=8.5$ Hz), 7.39–7.52 (5H, m), 7.63 (1H, d, $J=16.1$ Hz), 7.71 (2H, d, $J=8.5$ Hz), 8.88 (1H, d, $J=8.7$ Hz);

MASS (ES+): m/e 402.

35 Preparation 25

Compound (25) (1.35 g) was obtained in a manner similar to Preparation 8. The obtained Compound (25) was used in Example 4.

¹H-NMR (300 MHz, CDCl₃, δ): 1.60 (3H, br), 1.85 (3H, br), 2.07 (3H, s), 3.66 (1H, br), 3.97 (1H, br), 5.00 (1H, br), 5.05 (2H, s),
5 6.06 (1H, d, J=8.4 Hz), 6.18 (1H, d, J=7.4 Hz), 6.92 (2H, d, J=8.7 Hz), 7.11 (2H, d, J=8.5 Hz), 7.23 (2H, d, J=8.0 Hz), 7.32-7.47 (8H, m), 7.69 (1H, d, J=15.8 Hz).

Preparation 26

Compound (26) (10.5 g) was obtained in a manner similar to
10 Preparation 1.

¹H-NMR (300 MHz, CDCl₃, δ): 4.07 (2H, m), 4.15 (2H, m), 5.89 (1H, s), 7.41 (1H, t, J=7.7 Hz), 7.49 (2H, t, J=7.4 Hz), 7.53 (1H, t, J=7.7 Hz), 7.65-7.75 (5H, m), 7.84 (1H, d, J=7.7 Hz), 7.89 (2H, d, J=8.0 Hz), 7.95 (1H, s);
15 MASS (ES⁺): m/e 331 (M+1).

Preparation 27

Compound (27) (6.7 g) was obtained in a manner similar to Preparation 2.

Preparation 28

Compound (28) (4.3 g) was obtained in a manner similar to
20 Preparation 3.

¹H-NMR (300 MHz, DMSO-d₆, δ): 4.03 (2H, m), 4.12 (2H, m), 5.25 (1H, s), 5.76 (1H, s), 7.34 (1H, d, J=7.1 Hz), 7.41 (1H, t, J=7.6 Hz), 7.43 (1H, d, J=7.3 Hz), 7.50-7.58 (4H, m), 7.60 (1H, s), 7.66 (2H, d, J=8.5 Hz), 7.71 (2H, d, J=7.6 Hz).
25

Preparation 29

Compound (29) (1.44 g) was obtained in a manner similar to Preparation 4.

¹H-NMR (300 MHz, CDCl₃, δ): 2.10 (3H, s), 4.03 (2H, m), 4.12 (2H, m), 5.79 (1H, s), 6.04 (1H, br), 6.32 (1H, d, J=8.0 Hz), 7.24-7.32 (3H, m), 7.33-7.46 (6H, m), 7.53-7.59 (4H, m);
30 MASS (ES⁺): m/z 392 (M+H₂O+1).

Preparation 30

Compound (30) (1.26 g) was obtained in a manner similar to
35 Preparation 5.

¹H-NMR (300 MHz, CDCl₃, δ): 2.12 (3H, s), 6.13 (1H, d, J=7.6 Hz), 6.36 (1H, d, J=7.6 Hz), 7.28 (2H, d, J=8.1 Hz), 7.36 (1H, m), 7.44 (2H, t, J=7.0 Hz), 7.53-7.59 (6H, m), 7.82 (2H, m), 10.0 (1H, s);

5 MASS (ES+): m/e 330 (M+1).

Preparation 31

Compound (31) (1.53 g) was obtained in a manner similar to Preparation 6.

¹H-NMR (300 MHz, CDCl₃, δ): 1.32 (3H, t, J=7.0 Hz), 2.01 (3H, s), 10 4.24 (2H, q, J=7.0 Hz), 6.30 (1H, d, J=7.9 Hz), 6.40 (1H, d, J=16.0 Hz), 6.54 (1H, d, J=8.0 Hz);

MASS (ES+): m/z 400 (M+1).

Preparation 32

Compound (32) (1.28 g) was obtained in a manner similar to 15 Preparation 7.

¹H-NMR (300 MHz, DMSO-d₆, δ): 2.05 (3H, s), 6.27 (1H, d, J=8.3 Hz), 6.61 (1H, d, J=16.0 Hz), 7.42-7.49 (4H, m), 7.54 (2H, t, J=7.5 Hz), 7.65 (1H, d, J=15.7 Hz), 7.66 (1H, m), 7.69-7.74 (4H, m), 7.79 (1H, s), 8.96 (1H, d, J=8.4 Hz);

20 MASS (ES-): m/z 370 (M-1).

Preparation 33

Compound (33) (1.20 g) was obtained in a manner similar to Preparation 8. The obtained Compound (33) was used in Example 5.

¹H-NMR (300 MHz, DMSO-d₆, δ): 1.53 (3H, br), 1.67 (3H, br), 1.96 25 (3H, s), 3.72 (1H, br), 3.94 (1H, br), 4.90 (1H, s), 6.18 (1H, d, J=8.2 Hz), 6.49 (1H, d, J=16.1 Hz), 7.33-7.40 (5H, m), 7.43-7.48 (4H, m), 7.57 (1H, br), 7.62-7.66 (4H, m), 8.88 (1H, d, J=8.4 Hz).

Preparation 34

To a solution of 1,1'-biphenyl-4-yl[3-(1,3-dioxolan-2-yl)phenyl]methanamine in dichloromethane (20 mL) were added 30 methanesulfonyl chloride and N-ethyl-N,N-diisopropylamine at 5°C, and the mixture was stirred at 5°C for 5 min. The mixture was warmed to ambient temperature and stirred for 30 min. The reaction mixture was diluted with ethyl acetate, washed with 35 saturated aqueous ammonium chloride solution, water, saturated

aqueous sodium hydrogen carbonate solution and brine, and dried over sodium sulfate. The solvent was removed in vacuo to give Compound (34) (1.82 g), which was used in the next reaction without further purification.

- 5 $^1\text{H-NMR}$ (300 MHz, CDCl_3 , δ): 2.72 (3H, s), 4.04 (2H, m), 4.12 (2H, m), 5.06 (1H, d, $J=7.0$ Hz), 5.78 (1H, s), 5.83 (1H, d, $J=7.4$ Hz), 7.32–7.47 (8H, m), 7.51 (1H, s), 7.54–7.60 (4H, m);
MASS (ES⁺): m/z 410 (M+1).

Preparation 35

- 10 Compound (35) (1.56 g) was obtained in a manner similar to Preparation 5.

- $^1\text{H-NMR}$ (300 MHz, CDCl_3 , δ): 2.79 (3H, s), 5.07 (1H, d, $J=7.2$ Hz), 5.90 (1H, d, $J=6.9$ Hz), 7.37 (3H, m), 7.45 (2H, d, $J=7.4$ Hz), 7.55–7.63 (5H, m), 7.68 (1H, d, $J=7.7$ Hz), 7.85 (1H, d, $J=7.5$ Hz),
15 7.91 (1H, s), 10.02 (1H, s);
MASS (ES⁻): m/z 364 (M-1).

Preparation 36

Compound (36) (3.24 g) was obtained in a manner similar to Preparation 6.

- 20 $^1\text{H-NMR}$ (300 MHz, CDCl_3 , δ): 1.32 (3H, t, $J=7.0$ Hz), 2.77 (3H, s), 4.24 (2H, q, $J=7.0$ Hz), 5.14 (1H, d, $J=7.0$ Hz), 5.84 (1H, d, $J=7.0$ Hz), 6.44 (1H, d, $J=15.8$ Hz);
MASS (ES⁺): m/z 436 (M+1).

Preparation 37

- 25 Compound (37) (1.55 g) was obtained in a manner similar to Preparation 7.

- $^1\text{H-NMR}$ (300 MHz, DMSO-d_6 , δ): 2.81 (3H, s), 5.82 (1H, d, $J=9.6$ Hz), 6.37 (1H, d, $J=16.0$ Hz), 7.44 (1H, m), 7.50–7.62 (6H, m), 7.73 (4H, m), 7.66 (2H, m), 7.93 (1H, s), 8.50 (1H, d, $J=9.5$ Hz);
30 MASS (ES⁺): m/z 406 (M-1).

Preparation 38

Compound (38) (1.28 g) was obtained in a manner similar to Preparation 8. The obtained Compound (38) was used in Example 6.

- $^1\text{H-NMR}$ (300 MHz, CDCl_3 , δ): 1.53 (3H, br), 1.69 (3H, br), 2.73 (3H, s), 3.53 (1H, br), 3.94 (1H, br), 4.91 (1H, br), 5.73 (1H, br),
35

6.51 (1H, d, J=16.1 Hz), 7.36 (1H, m), 7.43–7.51 (8H, m), 7.72 (1H, s), 8.41 (1H, br).

Preparation 39

Compound (39) (5.05 g) was obtained in a manner similar to Preparation 1.

¹H-NMR (300 MHz, CDCl₃, δ): 4.06 (2H, m), 4.14 (2H, m), 5.86 (1H, s), 7.47 (2H, d, J=8.0 Hz), 7.52 (1H, d, J=7.5 Hz), 7.72 (2H, d, J=7.1 Hz), 7.77 (2H, d, J=7.2 Hz), 7.89 (1H, s).

Preparation 40

Compound (40) (5.95 g) was obtained in a manner similar to Preparation 2.

Preparation 41

Compound (41) (4.43 g) was obtained in a manner similar to Preparation 3.

¹H-NMR (300 MHz, CDCl₃, δ): 4.04 (2H, m), 4.13 (2H, m), 5.21 (1H, s), 5.78 (1H, s), 7.27–7.38 (6H, m), 7.49 (1H, s);

MASS (ES⁺): m/e 273 (M–NH₂).

Preparation 42

Compound (42) (2.42 g) was obtained in a manner similar to Preparation 9.

¹H-NMR (300 MHz, CDCl₃, δ): 4.03 (2H, m), 4.11 (2H, m), 5.77 (1H, s), 6.44 (1H, d, J=7.7 Hz), 6.63 (1H, br.d, J=8.4 Hz), 7.23 (2H, d, J=7.4 Hz), 7.32 (2H, d, J=8.7 Hz), 7.35–7.55 (6H, m), 7.80 (2H, d, J=7.0 Hz);

MASS (ES⁺): m/e 394 (M+1).

Preparation 43

Compound (43) (1.86 g) was obtained in a manner similar to Preparation 5.

¹H-NMR (300 MHz, CDCl₃, δ): 6.49 (1H, d, J=7.6 Hz), 6.65 (1H, br.d, J=7.6 Hz), 7.23 (2H, d, J=8.4 Hz), 7.35 (2H, d, J=8.5 Hz), 7.46 (2H, t, J=7.4 Hz), 7.55 (2H, t, J=7.1 Hz), 7.58 (1H, d, J=8.5 Hz), 7.82 (4H, m), 10.00 (1H, s);

MASS (ES⁺): m/e 350 (M+1).

Preparation 44

Compound (44) (2.23 g) was obtained in a manner similar to

Preparation 11.

¹H-NMR (300 MHz, CDCl₃, δ): 1.33 (3H, t, J=7.1 Hz), 4.25 (2H, q, J=7.1 Hz), 6.40 (1H, d, J=15.7 Hz), 6.44 (1H, d, J=7.0 Hz).

Preparation 45

5 Compound (45) (1.82 g) was obtained in a manner similar to Preparation 7.

¹H-NMR (300 MHz, CDCl₃, δ): 6.39 (1H, d, J=16.2 Hz), 6.44 (1H, d, J=7.3 Hz), 7.05 (1H, br), 7.24 (2H, d, J=8.0 Hz), 7.30-7.40 (4H, m), 7.42-7.56 (5H, m), 7.65 (1H, d, J=15.7 Hz), 7.83 (2H, d, J=7.0 Hz).

Preparation 46

Compound (46) (2.09 g) was obtained in a manner similar to Preparation 8. The obtained Compound (46) was used in Example 7.

¹H-NMR (300 MHz, CDCl₃, δ): 1.62 (3H, br), 1.82 (3H, br), 3.65 (1H, m), 3.95 (1H, m), 4.97 (1H, br), 6.42 (1H, d, J=7.0 Hz), 6.82 (1H, br.d, J=7.0 Hz), 7.22 (2H, d, J=8.5 Hz), 7.29-7.56 (8H, m), 7.63 (1H, d, J=15.7 Hz), 7.83 (2H, d, J=7.0 Hz);

MASS (ES⁺): m/e 491 (M+1).

Preparation 47

20 Compound (47) (2.5 g) was obtained in a manner similar to Preparation 4.

¹H-NMR (300 MHz, CDCl₃, δ): 4.04 (2H, m), 4.11 (2H, m), 5.76 (1H, s), 6.03 (1H, br.d, J=8.3 Hz), 6.24 (1H, d, J=8.1 Hz), 7.17 (3H, m), 7.17-7.45 (5H, m);

25 MASS (ES⁺): m/e 332 (M+1).

Preparation 48

Compound (48) (1.98 g) was obtained in a manner similar to Preparation 5.

¹H-NMR (300 MHz, CDCl₃, δ): 2.09 (3H, s), 6.10 (1H, br, J=7.3 Hz), 6.29 (1H, d, J=7.6 Hz), 7.15 (2H, d, J=8.4 Hz), 7.32 (2H, d, J=8.5 Hz), 7.49 (1H, d, J=7.8 Hz), 7.53 (1H, t, J=7.6 Hz), 7.75 (1H, s), 7.80 (1H, d, J=6.7 Hz), 9.99 (1H, s);

MASS (ES⁻): m/e 286 (M-1).

Preparation 49

35 Compound (49) (2.41 g) was obtained in a manner similar to

Preparation 6.

¹H-NMR (300 MHz, CDCl₃, δ): 1.33 (3H, t, J=7.1 Hz), 2.09 (3H, s), 4.26 (2H, q, J=7.1 Hz), 6.02 (1H, br, J=8.4 Hz), 6.23 (1H, d, J=8.4 Hz), 6.40 (1H, d, J=16.1 Hz).

5 Preparation 50

Compound (50) (2.27 g) was obtained in a manner similar to Preparation 7.

¹H-NMR (300 MHz, CDCl₃, δ): 2.08 (3H, s), 6.22 (1H, m), 6.39 (1H, d, J=16.0 Hz), 7.17 (2H, d, J=8.4 Hz), 7.24 (1H, d, J=7.8 Hz), 10 7.31 (2H, d, J=8.6 Hz), 7.36 (1H, t, J=7.8 Hz), 7.38 (1H, s), 7.45 (1H, d, J=7.6 Hz), 7.64 (1H, d, J=16.0 Hz).

Preparation 51

Compound (51) (2.76 g) was obtained in a manner similar to Preparation 8. The obtained Compound (51) was used in Example 8.

15 ¹H-NMR (300 MHz, CDCl₃, δ): 1.55-1.71 (3H, br), 1.77-1.93 (3H, br), 2.09 (3H, s), 3.65 (1H, m), 3.97 (1H, m), 4.99 (1H, m), 6.22 (1H, d, J=8.7 Hz), 6.30 (1H, br), 7.15 (2H, d, J=8.5 Hz), 7.20 (1H, m), 7.27 (2H, d, J=8.0 Hz), 7.33 (1H, s), 7.34-7.44 (1H, m), 7.64 (1H, d, J=15.9 Hz);

20 MASS (ES⁺): m/e 429 (M+1).

Preparation 52

Compound (52) (1.65 g) was obtained in a manner similar to Preparation 9.

¹H-NMR (300 MHz, CDCl₃, δ): 1.40 (3H, t, J=7.0 Hz), 4.01 (2H, q, J=7.0 Hz), 4.00 (2H, m), 4.09 (2H, m), 5.77 (1H, s), 6.42 (1H, d, J=7.5 Hz), 6.64 (1H, d, J=7.8 Hz), 6.85 (2H, d, J=8.4 Hz), 7.18 (2H, d, J=8.4 Hz), 7.30 (1H, d, J=7.3 Hz), 7.36 (1H, t, J=7.7 Hz), 7.41 (1H, br.s), 7.44 (2H, d, J=7.6 Hz), 7.50 (1H, d, J=7.0 Hz), 7.80 (2H, d, J=8.5 Hz);

30 MASS (ES⁺): m/e 404 (M+1).

Preparation 53

Compound (53) (1.50 g) was obtained in a manner similar to Preparation 5.

¹H-NMR (300 MHz, CDCl₃, δ): 1.41 (3H, t, J=7.0 Hz), 4.02 (2H, q, J=7.0 Hz), 6.44 (1H, d, J=7.3 Hz), 6.69 (1H, d, J=7.3 Hz), 6.87

(2H, d, J=8.8 Hz), 7.17 (2H, d, J=8.8 Hz), 7.44 (2H, m), 7.49-7.55 (2H, m), 7.60 (1H, d, J=7.8 Hz), 7.81 (4H, m), 9.98 (1H, s).

Preparation 54

Compound (54) (1.80 g) was obtained in a manner similar to

5 Preparation 6.

¹H-NMR (300 MHz, CDCl₃, δ): 1.32 (3H, t, J=7.1 Hz), 1.41 (3H, t, J=6.9 Hz), 4.02 (2H, q, J=6.9 Hz), 4.24 (2H, q, J=7.1 Hz), 6.38 (1H, d, J=16.3 Hz), 6.40 (1H, d, J=7.0 Hz), 6.74 (1H, d, J=7.4 Hz), 6.86 (2H, d, J=8.7 Hz), 7.18 (2H, d, J=8.8 Hz).

10 Preparation 55

Compound (55) (1.49 g) was obtained in a manner similar to Preparation 7.

¹H-NMR (300 MHz, CDCl₃, δ): 1.41 (3H, t, J=7.0 Hz), 4.03 (2H, q, J=7.0 Hz), 6.38 (1H, d, J=16.1 Hz), 6.40 (1H, d, J=7.4 Hz), 6.88 (2H, d, J=8.8 Hz), 7.09 (2H, d, J=8.1 Hz), 7.19 (2H, d, J=8.3 Hz), 7.36 (2H, m), 7.41-7.48 (4H, m), 7.53 (1H, m), 7.65 (1H, d, J=15.8 Hz), 7.83 (2H, d, J=7.0 Hz).

Preparation 56

Compound (56) (1.74 g) was obtained in a manner similar to

20 Preparation 8. The obtained Compound (56) was used in Example 9.

¹H-NMR (300 MHz, CDCl₃, δ): 1.41 (3H, t, J=7.0 Hz), 1.60 (3H, br), 1.82 (3H, br), 3.64 (1H, br), 3.96 (1H, br), 4.02 (2H, q, J=7.0 Hz), 4.98 (1H, br), 6.39 (1H, d, J=8.0 Hz), 6.72 (1H, d, J=8.0 Hz), 6.87 (1H, d, J=8.8 Hz), 7.17 (2H, d, J=8.8 Hz), 7.32 (2H, m), 7.36-7.47 (4H, m), 7.52 (1H, m), 7.65 (1H, d, J=15.7 Hz), 7.82 (2H, d, J=7.5 Hz);

MASS (ES⁺): m/e 501 (M+1).

Preparation 57

Compound (57) (6.7 g) was obtained in a manner similar to

30 Preparation 1.

¹H-NMR (300 MHz, CDCl₃, δ): 1.46 (3H, t, J=7.0 Hz), 4.07 (2H, m), 4.14 (2+2H, m), 5.87 (1H, s), 6.95 (2H, d, J=8.7 Hz), 7.50 (1H, t, J=7.5 Hz), 7.69 (1H, d, J=7.7 Hz), 7.76 (1H, d, J=7.7 Hz), 7.81 (2H, d, J=8.8 Hz), 7.87 (1H, s).

35 Preparation 58

Compound (58) (3.72 g) was obtained in a manner similar to Preparation 2.

MASS (ES+): m/e 314 (M+1).

Preparation 59

5 Compound (59) (3.42 g) was obtained in a manner similar to Preparation 3.

¹H-NMR (300 MHz, CDCl₃, δ): 1.39 (3H, t, J=7.0 Hz), 4.00 (2H, q, J=7.0 Hz), 4.02 (2H, m), 4.12 (2H, m), 5.18 (1H, s), 5.78 (1H, s), 6.82 (2H, d, J=8.7 Hz), 7.25 (2H, d, J=8.2 Hz), 7.34 (3H, m),
10 7.51 (1H, br.s);

MASS (ES+): m/e 283 (M-NH₂).

Preparation 60

Compound (60) (2.42 g) was obtained in a manner similar to Preparation 4.

15 ¹H-NMR (300 MHz, CDCl₃, δ): 1.40 (3H, t, J=6.9 Hz), 2.06 (3H, s), 4.01 (2H, q, J=6.9 Hz), 4.03 (2H, m), 4.10 (2H, m), 5.77 (1H, s), 6.01 (1H, d, J=7.3 Hz), 6.22 (1H, d, J=8.1 Hz), 6.83 (2H, d, J=8.8 Hz), 7.11 (2H, d, J=8.6 Hz), 7.21 (1H, d, J=7.3 Hz), 7.41-7.88 (3H, m);

20 MASS (ES+): m/e 342 (M+1).

Preparation 61

Compound (61) (1.69 g) was obtained in a manner similar to Preparation 5.

¹H-NMR (300 MHz, CDCl₃, δ): 1.41 (3H, t, J=7.0 Hz), 2.10 (3H, s),
25 4.02 (2H, q, J=7.0 Hz), 6.02 (1H, d, J=6.9 Hz), 6.25 (1H, d, J=7.3 Hz), 6.86 (2H, d, J=8.7 Hz), 7.10 (2H, d, J=8.9 Hz), 7.52 (2H, m), 7.78 (2H, m), 10.00 (1H, s).

Preparation 62

30 Compound (62) (2.09 g) was obtained in a manner similar to Preparation 6.

¹H-NMR (300 MHz, CDCl₃, δ): 1.32 (3H, t, J=7.1 Hz), 1.40 (3H, t, J=7.0 Hz), 2.06 (3H, s), 4.00 (2H, q, J=6.9 Hz), 4.24 (2H, q, J=7.1 Hz), 6.20 (1H, d, J=8.2 Hz), 6.38 (1H, d, J=16.1 Hz), 6.40 (1H, d, J=6.5 Hz), 6.83 (2H, d, J=8.9 Hz), 7.11 (2H, d, J=8.8 Hz).

35 Preparation 63

Compound (63) (1.84 g) was obtained in a manner similar to Preparation 7.

¹H-NMR (300 MHz, CDCl₃, δ): 1.41 (3H, t, J=7.0 Hz), 2.07 (3H, s), 4.02 (2H, q, J=7.0 Hz), 6.18 (1H, m), 6.39 (1H, d, J=16.0 Hz), 6.85 (2H, d, J=8.8 Hz), 7.12 (2H, d, J=8.4 Hz), 7.27 (1H, d, J=8.4 Hz), 7.27 (1H, d, J=7.7 Hz), 7.35 (1H, t, J=7.8 Hz), 7.40 (1H, s), 7.44 (1H, d, J=7.8 Hz), 7.64 (1H, d, J=16.0 Hz).

Preparation 64

Compound (64) (1.69 g) was obtained in a manner similar to Preparation 8. The obtained Compound (64) was used in Example 10.

¹H-NMR (300 MHz, CDCl₃, δ): 1.41 (3H, t, J=7.0 Hz), 1.61 (3H, br), 1.85 (3H, br), 2.08 (3H, s), 3.65 (1H, br), 3.97 (1H, br), 4.01 (2H, q, J=7.0 Hz), 5.00 (1H, br), 6.09 (1H, br), 6.19 (1H, d, J=8.5 Hz), 6.85 (2H, d, J=8.4 Hz), 7.10 (2H, d, J=8.8 Hz), 7.23 (1H, d, J=7.6 Hz), 7.24-7.30 (3H, m), 7.67 (1H, d, J=15.8 Hz); MASS (ES⁻): m/e 437 (M-1).

Preparation 65

Compound (65) (1.12 g) was obtained in a manner similar to Preparation 5.

¹H-NMR (300 MHz, CDCl₃, δ): 5.96 (2H, s), 6.40 (1H, d, J=7.0 Hz), 6.67 (1H, d, J=7.0 Hz), 6.73 (1H, s), 6.78 (2H, m), 7.43-7.55 (4H, m), 7.59 (1H, d, J=7.6 Hz), 7.82 (4H, m), 9.99 (1H, s).

Preparation 66

Compound (66) (1.34 g) was obtained in a manner similar to Preparation 6.

¹H-NMR (300 MHz, CDCl₃, δ): 1.33 (3H, t, J=7.0 Hz), 4.25 (2H, q, J=7.0 Hz), 5.97 (2H, s), 6.36 (1H, d, J=8.4 Hz), 6.40 (1H, d, J=16.1 Hz), 6.61 (1H, br), 6.75 (1H, s), 6.78 (2H, s).

Preparation 67

Compound (67) (856 mg) was obtained in a manner similar to Preparation 7.

¹H-NMR (300 MHz, CDCl₃, δ): 5.97 (2H, s), 6.36 (1H, d, J=7.7 Hz), 6.39 (1H, d, J=16.0 Hz), 6.77 (1H, s), 6.79 (2H, s), 7.33-7.55 (8H, m), 7.65 (1H, d, J=16.0 Hz), 7.83 (2H, d, J=7.0 Hz).

Preparation 68

- Compound (68) (988 mg) was obtained in a manner similar to Preparation 8. The obtained Compound (68) was used in Example 11.
- ¹H-NMR (300 MHz, CDCl₃, δ): 1.59 (3H, br), 1.82 (3H, br), 3.64 (1H, m), 3.95 (1H, m), 4.98 (1H, br.s), 5.95 (2H, s), 6.34 (1H, d, J=8.0 Hz), 6.74 (1H, s), 6.77 (2H, s), 7.31-7.55 (8H, m), 7.63 (1H, m), 7.83 (2H, d, J=7.0 Hz).

Preparation 69

- Compound (69) (2.61 g) was obtained in a manner similar to Preparation 1.
- ¹H-NMR (300 MHz, CDCl₃, δ): 4.06 (2H, m), 4.13 (2H, m), 5.87 (1H, s), 6.07 (2H, s), 6.86 (1H, d, J=8.4 Hz), 7.36 (2H, m), 7.49 (1H, t, J=7.6 Hz), 7.69 (1H, d, J=8.0 Hz), 7.74 (1H, d, J=7.7 Hz), 7.86 (1H, s).

Preparation 70

- Compound (70) (3.65 g) was obtained in a manner similar to Preparation 2.
- MASS (ES⁻): m/e 314 (M+1).

Preparation 71

- Compound (71) (2.22 g) was obtained in a manner similar to Preparation 3.
- ¹H-NMR (300 MHz, CDCl₃, δ): 4.03 (2H, m), 4.13 (2H, m), 5.15 (1H, s), 5.78 (1H, s), 5.91 (2H, s), 6.73 (1H, d, J=8.4 Hz), 6.84 (2H, m), 7.34 (3H, m), 7.50 (1H, s).

Preparation 72

- Compound (72) (1.39 g) was obtained in a manner similar to Preparation 9.
- ¹H-NMR (300 MHz, CDCl₃, δ): 3.99-4.06 (2H, m), 4.06-4.17 (2H, m), 5.78 (1H, s), 5.94 (1H, s), 6.37 (1H, d, J=7.8 Hz), 6.62 (1H, d, J=7.8 Hz), 6.76 (1H, s), 6.77 (2H, s), 7.29 (1H, d, J=7.4 Hz), 7.37 (1H, t, J=7.2 Hz), 7.41-7.54 (4H, m), 7.62 (1H, t, J=8.0 Hz), 7.8 (2H, d, J=7.0 Hz).

Preparation 73

- Compound (73) (1.41 g) was obtained in a manner similar to Preparation 4.
- ¹H-NMR (300 MHz, CDCl₃, δ): 2.06 (3H, s), 4.02 (2H, m), 4.13 (2H,

m), 5.77 (1H, s), 5.94 (2H, s), 6.02 (1H, br.d, J=8.1 Hz), 6.17 (1H, d, J=8.1 Hz), 6.68 (1H, s), 9.72 (1H, d, J=8.0 Hz), 6.74 (1H, t, J=8.0 Hz), 7.21 (1H, d, J=8.0 Hz), 7.28-7.42 (3H, m);
MASS (ES+): m/e 342 (M+1).

5 Preparation 74

Compound (74) (1.11 g) was obtained in a manner similar to Preparation 5.

¹H-NMR (300 MHz, CDCl₃, δ): 2.09 (3H, s), 5.96 (2H, s), 6.05 (1H, br.d, J=8.0 Hz), 6.21 (1H, d, J=8.0 Hz), 6.67 (2H, m), 6.77 (1H, d, J=7.8 Hz), 7.51 (2H, m), 7.78 (2H, m), 9.99 (1H, s).

Preparation 75

Compound (75) (1.37 g) was obtained in a manner similar to Preparation 6.

¹H-NMR (300 MHz, CDCl₃, δ): 1.33 (3H, t, J=7.0 Hz), 2.09 (3H, s), 4.26 (2H, q, J=7.0 Hz), 5.96 (2H, s), 6.00 (1H, br), 6.16 (1H, d, J=7.9 Hz), 6.69 (2H, d, J=9.6 Hz), 6.77 (1H, d, J=8.1 Hz).

Preparation 76

Compound (76) (973 mg) was obtained in a manner similar to Preparation 7.

¹H-NMR (300 MHz, CDCl₃, δ): 2.07 (3H, s), 5.95 (2H, s), 6.14 (1H, s), 6.39 (1H, d, J=16.0 Hz), 6.69 (1H, s), 6.70 (1H, d, J=7.7 Hz), 6.75 (1H, t, J=8.8 Hz), 7.26 (1H, d, J=6.8 Hz), 7.35 (1H, t, J=7.7 Hz), 7.40 (1H, s), 7.44 (1H, d, J=7.6 Hz), 7.62 (1H, m), 7.65 (1H, d, J=16.0 Hz).

25 Preparation 77

Compound (77) (1.35 g) was obtained in a manner similar to Preparation 8. The obtained Compound (77) was used in Example 12.

¹H-NMR (300 MHz, CDCl₃, δ): 1.72-1.56 (3H, br), 1.92-1.83 (3H, br), 3.65 (1H, m), 3.99 (1H, m), 5.00 (1H, m), 5.95 (2H, s), 6.14 (1H, s), 6.36 (1H, br), 6.68 (1H, s), 6.69 (1H, d, J=8.1 Hz), 6.77 (1H, d, J=7.8 Hz), 7.21 (1H, d, J=8.7 Hz), 7.33 (1H, t, J=7.4 Hz), 7.38 (1H, s), 7.40 (1H, d, J=8.0 Hz), 7.65 (1H, d, J=16.8 Hz);
MASS (ES-): m/e 437 (M-1).

Preparation 78

35 Compound (78) (3.2 g) was obtained in a manner similar to

Preparation 1.

¹H-NMR (300 MHz, CDCl₃, δ): 1.24 (6H, t, J=7.0 Hz), 3.57 (4H, m), 4.22 (2H, s), 5.04 (2H, s), 5.53 (1H, s), 6.93 (2H, d, J=8.5 Hz), 7.18 (2H, d, J=8.5 Hz), 7.29-7.43 (5H, m), 7.56 (2H, d, J=8.4 Hz), 8.00 (2H, d, J=8.4 Hz).

Preparation 79

To a suspension of 2-[4-(benzyloxy)phenyl]-1-[4-(diethoxymethyl)phenyl]ethanone (1.5 g) was added sodium borohydride (140 mg) at 5°C, and immediately after that, the mixture was allowed to warm to ambient temperature and stirred for 1 hr. The solvent was removed in vacuo, and the residue was diluted with ethyl acetate. The organic phase was sequentially washed with water, saturated aqueous ammonium chloride solution and brine, and dried over sodium sulfate. The solvent was removed in vacuo to give Compound (79) (1.51 g) as colorless oil.

¹H-NMR (300 MHz, CDCl₃, δ): 1.24 (6H, t, J=7.0 Hz), 1.94 (1H, d, J=3.0 Hz), 2.90 (1H, dd, J=13.6, 8.4 Hz), 2.98 (1H, dd, J=13.6, 4.8 Hz), 3.48-3.67 (4H, m), 4.86 (1H, m), 5.05 (2H, s), 5.51 (1H, s), 6.91 (2H, d, J=8.7 Hz), 7.11 (2H, d, J=8.7 Hz), 7.32-7.39 (5H, m), 7.40-7.47 (4H, m).

Preparation 80

Compound (80) (838 mg) was obtained in a manner similar to Preparation 5.

¹H-NMR (300 MHz, CDCl₃, δ): 2.10 (1H, d, J=3.4 Hz), 2.90 (2H, dd, J=13.6, 8.3 Hz), 3.01 (2H, dd, J=13.6, 4.7 Hz), 4.94 (1H, m), 5.05 (2H, s), 6.93 (2H, d, J=8.5 Hz), 7.08 (2H, d, J=8.5 Hz), 7.33-7.45 (5H, m), 7.50 (2H, d, J=8.0 Hz), 7.85 (2H, d, J=8.0 Hz), 10.00 (1H, s).

Preparation 81

Compound (81) (1.01 g) was obtained in a manner similar to Preparation 6.

¹H-NMR (300 MHz, CDCl₃, δ): 1.34 (3H, t, J=7.0 Hz), 2.01 (1H, d, J=3.4 Hz), 2.90 (1H, dd, J=13.6, 8.3 Hz), 2.99 (1H, dd, J=13.6, 5.0 Hz), 4.27 (2H, q, J=7.0 Hz), 4.87 (1H, m), 5.05 (2H, s), 6.43 (1H, d, J=16.0 Hz), 6.92 (2H, d, J=8.9 Hz), 7.09 (2H, d, J=8.9

Hz), 7.32-7.45 (7H, m), 7.50 (2H, d, J=8.3 Hz), 7.68 (1H, d, J=16.0 Hz).

Preparation 82

Compound (82) (300 mg) was obtained in a manner similar to Preparation 7.

¹H-NMR (300 MHz, DMSO-d₆, δ): 2.81 (2H, m), 4.65 (1H, t, J=6.6 Hz), 5.04 (2H, s), 6.41 (1H, d, J=8.8 Hz), 7.05 (2H, d, J=8.8 Hz), 7.23-7.48 (10H, m).

Preparation 83

Compound (83) (337 mg) was obtained in a manner similar to Preparation 8. The obtained Compound (83) was used in Example 13. ¹H-NMR (300 MHz, CDCl₃, δ): 1.50-1.75 (6H, br), 2.81 (2H, m), 3.54 (1H, m), 3.96 (1H, m), 4.71 (1H, m), 4.90 (1H, s), 5.04 (2H, s), 5.31 (1H, d, J=4.5 Hz), 6.46 (1H, d, J=16.0 Hz), 6.86 (2H, d, J=8.6 Hz), 7.05 (2H, d, J=8.6 Hz), 7.35-7.50 (10H, m).

Preparation 84

To a solution of Compound (81) (394 mg) in N,N-dimethylformamide (8 mL) was added sodium hydride (60% in oil, 43.1 mg) at 5°C, and the mixture was stirred for 15 min. To the resulting mixture was added methyl iodide (0.091 mL) at 5°C, and the mixture was allowed to warm to ambient temperature and stirred for 3 hrs. The reaction mixture was poured into saturated aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The organic phase was sequentially washed with water, saturated aqueous ammonium chloride solution and brine, and dried over sodium sulfate. The solvent was removed in vacuo, and the residue was purified by preparative TLC (silica gel, hexane:ethyl acetate=2:1) to give Compound (84) (272 mg) as colorless oil.

¹H-NMR (300 MHz, CDCl₃, δ): 1.38 (3H, t, J=7.0 Hz), 2.82 (1H, dd, J=13.6, 6.2 Hz), 3.04 (1H, dd, J=13.6, 6.9 Hz), 3.21 (3H, s), 4.27 (2H, q, J=7.0 Hz), 4.29 (1H, m), 5.03 (2H, s), 6.44 (1H, d, J=16.0 Hz), 6.85 (2H, d, J=8.4 Hz), 6.98 (2H, d, J=8.4 Hz), 7.22 (2H, d, J=8.0 Hz), 7.33-7.49 (7H, m), 7.68 (1H, d, J=16.0 Hz).

Preparation 85

Compound (85) (160 mg) was obtained in a manner similar to Preparation 7.

¹H-NMR (300 MHz, CDCl₃, δ): 2.82 (1H, dd, J=15.3, 5.8 Hz), 3.06 (1H, dd, J=15.3, 6.7 Hz), 3.21 (3H, s), 4.31 (1H, t, J=8.3 Hz),
5 5.03 (2H, s), 6.44 (1H, d, J=16.0 Hz), 6.84 (2H, d, J=8.7 Hz),
6.98 (2H, d, J=8.7 Hz), 7.23 (2H, d, J=8.4 Hz), 7.32-7.44 (5H, m),
7.49 (2H, d, J=8.4 Hz), 7.76 (1H, d, J=16.0 Hz).

Preparation 86

Compound (86) (195 mg) was obtained in a manner similar to
10 Preparation 8. The obtained Compound (86) was used in Example 14.

¹H-NMR (300 MHz, CDCl₃, δ): 1.55-1.88 (6H, br), 2.81 (1H, dd, J=13.8, 6.1 Hz), 3.05 (1H, dd, J=13.8, 7.2 Hz), 3.20 (3H, s),
3.66 (1H, m), 3.97 (1H, m), 4.29 (1H, t, J=6.6 Hz), 5.02 (2+1H, s), 6.83 (2H, d, J=8.5 Hz), 6.97 (2H, d, J=8.5 Hz), 7.20 (2H, d,
15 J=8.1 Hz), 7.31-7.47 (7H, m), 7.73 (1H, d, J=16.0 Hz);
MASS (ES⁺): m/e 488 (M+1).

Preparation 87

Compound (87) (1.69 g) was obtained in a manner similar to Preparation 1.

20 ¹H-NMR (300 MHz, CDCl₃, δ): 3.08 (6H, s), 3.99-4.17 (4H, m), 5.87 (1H, s), 6.68 (2H, d, J=9.2 Hz), 7.47 (1H, dd, J=7.7, 7.7 Hz),
7.65 (1H, ddd, J=7.7, 1.4, 1.4 Hz), 7.72 (1H, ddd, J=7.7, 1.4, 1.4 Hz), 7.75-7.86 (3H, m);
MASS (ES⁺): m/e 298.13 (M+1).

Preparation 88

Compound (88) (6.0 g) was obtained in a manner similar to Preparation 2.

¹H-NMR (300 MHz, DMSO-d₆, δ): 2.91 (4H, s), 2.95 (2H, s), 3.89-4.07 (4H, m), 5.71 (0.3H, s), 5.74 (0.7H, s), 6.64-6.76 (2H, m),
30 7.15-7.31 (3H, m), 7.36-7.50 (3H, m), 10.84 (0.7H, s), 11.14 (0.3H, s);
MASS (ES⁺): m/e 313.16 (M+1).

Preparation 89

Compound (89) (5.03 g) was obtained in a manner similar to
35 Preparation 3.

$^1\text{H-NMR}$ (300 MHz, CDCl_3 , δ): 2.91 (6H, s), 3.96–4.16 (4H, m), 5.15 (1H, s), 5.78 (1H, s), 6.68 (2H, d, $J=8.8$ Hz), 7.20 (2H, d, $J=8.8$ Hz), 7.28–7.38 (3H, m), 7.52 (1H, s);

MASS (ES $^-$): m/e 297.19 (M–1).

5 Preparation 90

Compound (90) (1.52 g) was obtained in a manner similar to Preparation 9.

$^1\text{H-NMR}$ (300 MHz, CDCl_3 , δ): 2.93 (6H, s), 3.95–4.13 (4H, m), 5.79 (1H, s), 6.39 (1H, d, $J=8.4$ Hz), 6.56–6.66 (1H, m), 6.68 (2H, d, $J=8.4$ Hz), 7.13 (2H, d, $J=8.4$ Hz), 7.24–7.54 (7H, m), 7.76–7.86 (2H, m);

MASS (ES $^+$): m/e 403.20 (M+1).

Preparation 91

Compound (91) (1.21 g) was obtained in a manner similar to Preparation 10.

$^1\text{H-NMR}$ (300 MHz, DMSO-d_6 , δ): 2.87 (6H, s), 6.39 (1H, d, $J=8.8$ Hz), 6.70 (2H, d, $J=8.8$ Hz), 7.18 (2H, d, $J=8.8$ Hz), 7.44–7.63 (4H, m), 7.70 (1H, d, $J=8.1$ Hz), 7.81 (1H, d, $J=7.7$ Hz), 7.87–7.97 (3H, m), 9.24 (1H, d, $J=8.8$ Hz), 9.99 (1H, s);

MASS (ES $^+$): m/e 359.24 (M+1).

Preparation 92

Compound (92) (1.92 g) was obtained in a manner similar to Preparation 11.

$^1\text{H-NMR}$ (300 MHz, CDCl_3 , δ): 1.32 (3H, t, $J=7.0$ Hz), 2.95 (6H, s), 4.24 (2H, q, $J=7.0$ Hz), 6.34 (1H, d, $J=7.7$ Hz), 6.39 (1H, d, $J=16.1$ Hz), 6.62 (1H, d, $J=7.7$ Hz), 6.69 (2H, d, $J=8.4$ Hz), 7.12 (2H, d, $J=8.4$ Hz), 7.33–7.39 (2H, m), 7.39–7.56 (5H, m), 7.65 (1H, d, $J=16.1$ Hz), 7.77–7.86 (1H, m);

MASS (ES $^+$): m/e 429.15 (M+1).

30 Preparation 93

Compound (93) (1.30 g) was obtained in a manner similar to Preparation 12.

$^1\text{H-NMR}$ (300 MHz, DMSO-d_6 , δ): 2.86 (6H, s), 6.32 (1H, d, $J=8.4$ Hz), 6.50 (1H, d, $J=16.1$ Hz), 6.69 (2H, d, $J=8.8$ Hz), 7.17 (2H, d, $J=8.8$ Hz), 7.35–7.61 (7H, m), 7.73 (1H, s), 7.91 (2H, d, $J=8.1$

Hz), 9.13 (1H, d, J=8.4 Hz);

MASS (ES+): m/e 401.19 (M+1).

Preparation 94

Compound (94) (1.33 g) was obtained in a manner similar to
5 Preparation 13. The obtained Compound (94) was used in Example 15.
¹H-NMR (300 MHz, DMSO-d₆, δ): 1.54-1.84 (6H, m), 2.95 (6H, s),
3.54-3.67 (1H, m), 3.97-4.09 (1H, m), 4.99 (1H, s), 6.41 (1H, d,
J=8.4 Hz), 6.55 (1H, d, J=16.1 Hz), 6.79 (2H, d, J=8.8 Hz), 7.26
(2H, d, J=8.8 Hz), 7.45-7.72 (8H, m), 7.99-8.07 (2H, m), 9.26 (1H,
10 d, J=8.4 Hz), 11.35 (1H, s);
MASS (ES+): m/e 500.19 (M+1).

Preparation 95

Compound (95) (1.27 g) was obtained in a manner similar to
Preparation 4.
15 ¹H-NMR (300 MHz, CDCl₃, δ): 2.06 (3H, s), 2.93 (6H, s), 3.98-4.15
(4H, m), 5.79 (1H, s), 5.92-6.00 (1H, m), 6.20 (1H, d, J=8.1 Hz),
6.67 (2H, d, J=8.8 Hz), 7.06 (2H, d, J=8.8 Hz), 7.20-7.28 (1H, m),
7.29-7.43 (3H, m);
MASS (ES+): m/e 341.21 (M+1).

20 Preparation 96

Compound (96) (1.04 g) was obtained in a manner similar to
Preparation 5.
¹H-NMR (300 MHz, DMSO-d₆, δ): 1.92 (3H, s), 2.85 (6H, s), 6.07 (1H,
d, J=8.8 Hz), 6.67 (2H, d, J=8.8 Hz), 7.07 (2H, d, J=8.8 Hz),
25 7.52-7.62 (2H, m), 7.76-7.82 (2H, m), 8.74 (1H, d, J=8.8 Hz),
9.98 (1H, s);
MASS (ES+): m/e 297.23 (M+1).

Preparation 97

Compound (97) (2.38 g) was obtained in a manner similar to
30 Preparation 6.
¹H-NMR (300 MHz, CDCl₃, δ): 1.33 (3H, t, J=7.0 Hz), 2.07 (3H, s),
2.94 (6H, s), 4.25 (2H, q, J=7.0 Hz), 6.01 (1H, d, J=8.1 Hz),
6.15 (1H, d, J=8.1 Hz), 6.39 (1H, d, J=16.1 Hz), 6.67 (2H, d,
J=8.8 Hz), 7.05 (2H, d, J=8.8 Hz), 7.27-7.71 (5H, m);
35 MASS (ES+): m/e 367.19 (M+1).

Preparation 98

Compound (98) (780 mg) was obtained in a manner similar to Preparation 7.

¹H-NMR (300 MHz, DMSO-d₆, δ): 1.91 (3H, s), 2.84 (6H, s), 6.00 (1H, d, J=8.8 Hz), 6.49 (1H, d, J=16.1 Hz), 6.66 (2H, d, J=8.8 Hz), 7.07 (2H, d, J=8.8 Hz), 7.26-7.39 (2H, m), 7.49-7.64 (3H, m), 8.66 (1H, d, J=8.8 Hz);
MASS (ES+): m/e 339.21 (M+1).

Preparation 99

Compound (99) (915 mg) was obtained in a manner similar to Preparation 8. The obtained Compound (99) was used in Example 16.

¹H-NMR (300 MHz, DMSO-d₆, δ): 1.55-1.84 (6H, m), 2.00 (3H, s), 2.94 (6H, s), 3.58-3.67 (1H, m), 3.98-4.10 (1H, m), 5.00 (1H, s), 6.09 (1H, d, J=8.4 Hz), 6.55 (1H, d, J=16.1 Hz), 6.76 (2H, d, J=8.8 Hz), 7.16 (2H, d, J=8.8 Hz), 7.32-7.39 (1H, m), 7.41-7.61 (4H, m), 8.77 (1H, d, J=8.4 Hz), 11.36 (1H, s);
MASS (ES+): m/e 438.22 (M+1).

Example 1

To a stirred solution of Compound (8) (2.08 g) in methanol (38 mL) was added a solution of hydrogen chloride in methanol (hydrogen chloride methanol reagent 10, 9.5 mL, manufactured by Tokyo Kasei Co., Ltd.), and the mixture was stirred at ambient temperature for 1 hr. The solvent was removed in vacuo. The residue was dissolved in saturated aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate under basic conditions. The organic phase was washed with water and brine, and dried over sodium sulfate. The solvent was removed in vacuo, and the residue was triturated with diisopropyl ether to give Compound E1 as a colorless powder (1.42 g).
¹H-NMR (300 MHz, DMSO-d₆, δ): 1.90 (3H, s), 2.85 (6H, s), 5.98 (1H, d, J=8.3 Hz), 6.41 (1H, d, J=15.8 Hz), 6.67 (2H, d, J=8.8 Hz), 7.05 (2H, d, J=8.5 Hz), 7.27 (2H, d, J=8.5 Hz), 7.41 (1H, d, J=15.8 Hz), 7.49 (2H, d, J=7.8 Hz), 83.66 (1H, d, J=8.9 Hz);
MASS (ES+): m/e 354 (M+1).

Example 2

Compound E2 (1.45 g) was obtained from Compound (13) in a manner similar to Example 1.

¹H-NMR (300 MHz, DMSO-d₆, δ): 2.86 (6H, s), 6.30 (1H, d, J=8.4 Hz), 6.42 (1H, d, J=15.8 Hz), 6.69 (2H, d, J=8.8 Hz), 7.16 (2H, d, J=8.9 Hz), 7.37 (2H, d, J=8.0 Hz), 7.49 (6H, m), 7.92 (2H, d, J=8.4 Hz), 9.16 (1H, d, J=8.8 Hz);
MASS (ES⁺): m/e 416 (M+1).

Example 3

Compound E3 (419.7 mg) was obtained from Compound (18) in a manner similar to Example 1.

¹H-NMR (300 MHz, DMSO-d₆, δ): 1.57 (3H, d, J=7.0 Hz), 5.25 (1H, dq, J=7.0, 7.0 Hz), 6.51 (1H, d, J=16.0 Hz), 7.28 (1H, d, J=16.0 Hz), 7.40 (3H, m), 7.58 (4H, m), 7.96 (2H, d, J=8.1 Hz), 8.96 (1H, d, J=7.5 Hz);
MASS (ES⁺): m/e 311 (M+).

Example 4

Compound E4 (2.4 g) was obtained from Compound (25) in a manner similar to Example 1.

¹H-NMR (300 MHz, DMSO-d₆, δ): 1.91 (3H, s), 5.08 (2H, s), 6.03 (1H, d, J=8.8 Hz), 6.36 (1H, d, J=16.1 Hz), 6.96 (2H, d, J=8.7 Hz), 7.10 (1H, d, J=16.1 Hz), 7.17 (2H, d, J=8.8 Hz), 7.21 (2H, d, J=8.4 Hz), 7.28-7.37 (2H, m), 7.38-7.41 (2H, m), 7.42-7.46 (3H, m), 8.71 (1H, d, J=8.8 Hz);
MASS (ES⁻): m/e 415 (M-1).

Example 5

Compound E5 (912 mg) was obtained from Compound (33) in a manner similar to Example 1.

¹H-NMR (300 MHz, DMSO-d₆, δ): 1.96 (3H, s), 6.17 (1H, d, J=8.4 Hz), 6.45 (1H, d, J=15.8 Hz), 7.31-7.48 (9H, m), 7.55 (1H, s), 7.61-7.65 (4H, m), 8.86 (1H, d, J=8.8 Hz);
MASS (ES⁻): m/e 385 (M-1).

Example 6

Compound E6 (980 mg) was obtained from Compound (38) in a manner similar to Example 1.

¹H-NMR (300 MHz, DMSO-d₆, δ): 2.72 (3H, s), 5.73 (1H, br), 6.46

(4H, d, J=16.0 Hz), 7.33-7.40 (1H, m), 7.42-7.50 (7H, m), 7.62-7.70 (6H, m), 8.41 (1H, br);
MASS (ES+): m/e 423.

Example 7

5 Compound E7 (1.31 g) was obtained from Compound (46) in a manner similar to Example 1.

¹H-NMR (300 MHz, DMSO-d₆, δ): 6.40 (1H, d, J=15.7 Hz), 6.42 (1H, d, J=8.8 Hz), 7.23 (1H, d, J=15.7 Hz), 7.30 (1H, d, J=7.6 Hz), 7.35 (1H, t, J=7.6 Hz), 7.40-7.44 (3H, m), 7.45-7.53 (3H, m), 7.55 (2H, 10 br), 7.92 (2H, d, J=7.6 Hz), 9.31 (1H, d, J=8.4 Hz);
MASS (ES-): m/e 405 (M-1).

Example 8

 Compound E8 (1.60 g) was obtained from Compound (51) in a manner similar to Example 1.

15 ¹H-NMR (300 MHz, DMSO-d₆, δ): 1.94 (3H, s), 6.11 (1H, d, J=8.9 Hz), 6.38 (1H, d, J=16.0 Hz), 7.11 (1H, d, J=16.0 Hz), 7.16 (1H, d, J=7.6 Hz), 7.32 (2H, d, J=8.4 Hz), 7.34 (1H, m), 7.39 (1H, t, J=7.4 Hz), 7.40 (2H, d, J=8.8 Hz), 8.44 (1H, s), 8.84 (1H, d, J=8.8 Hz);
20 MASS (ES-): m/e 343 (M-1).

Example 9

 Compound E9 (1.18 g) was obtained from Compound (56) in a manner similar to Example 1.

25 ¹H-NMR (300 MHz, DMSO-d₆, δ): 1.31 (3H, t, J=7.0 Hz), 4.00 (2H, q, J=7.0 Hz), 6.36 (2H, d, J=8.4 Hz), 6.39 (1H, d, J=15.8 Hz), 6.9 (2H, d, J=8.4 Hz), 7.22 (1H, d, J=15.8 Hz), 7.26-7.40 (5H, m), 7.44-7.57 (4H, m), 7.92 (2H, d, J=7.0 Hz), 9.24 (1H, d, J=8.4 Hz);
MASS (ES+): m/e 417 (M+1).

30 Example 10

 Compound E10 (813.6 mg) was obtained from Compound (64) in a manner similar to Example 1.

¹H-NMR (300 MHz, DMSO-d₆, δ): 1.30 (3H, t, J=7.0 Hz), 1.92 (3H, s), 3.98 (2H, q, J=7.0 Hz), 6.05 (1H, d, J=8.3 Hz), 6.40 (1H, d, J=16.0 Hz), 6.87 (2H, d, J=8.9 Hz), 7.17 (2H, d, J=8.4 Hz), 7.22 35

(1H, d, J=7.0 Hz), 7.29-7.41 (3H, m), 7.45 (1H, s), 8.74 (1H, d, J=8.8 Hz);

MASS (ES-): m/e 353 (M-1).

Example 11

5 Compound E11 (651.6 mg) was obtained from Compound (68) in a manner similar to Example 1.

¹H-NMR (300 MHz, DMSO-d₆, δ): 5.99 (2H, s), 6.34 (1H, d, J=8.3 Hz), 6.42 (1H, d, J=16.1 Hz), 6.88 (2H, s), 6.99 (1H, s), 7.33-7.59 (8H, m), 7.92 (2H, d, J=8.0 Hz), 9.20 (1H, d, J=8.9 Hz);

10 MASS (ES-): m/e 415 (M-1).

Example 12

 Compound E12 (699.1 mg) was obtained from Compound (77) in a manner similar to Example 1.

15 ¹H-NMR (300 MHz, DMSO-d₆, δ): 1.93 (3H, s), 5.98 (2H, s), 6.03 (1H, d, J=8.1 Hz), 6.38 (1H, d, J=15.8 Hz), 6.77 (1H, d, J=8.0 Hz), 6.85 (1H, s), 6.85 (1H, d, J=8.1 Hz), 7.16 (1H, d, J=16.1 Hz), 7.17 (1H, d, J=7.0 Hz), 7.29 (1H, t, J=7.4 Hz), 7.43 (1H, s), 8.73 (1H, d, J=8.9 Hz);

MASS (ES-): m/e 353 (M-1).

Example 13

 Compound E13 (232.5 mg) was obtained from Compound (83) in a manner similar to Example 1.

25 ¹H-NMR (300 MHz, DMSO-d₆, δ): 2.80 (2H, m), 4.68 (1H, br), 5.04 (2H, s), 5.25 (1H, br), 6.37 (1H, d, J=16.0 Hz), 6.86 (2H, d, J=8.5 Hz), 7.05 (2H, d, J=8.5 Hz), 7.17 (1H, d, J=16.0 Hz), 7.26 (2H, d, J=8.1 Hz), 7.30-7.45 (7H, m);

MASS (ES+): m/e 390 (M+1).

Example 14

30 Compound E14 (123.1 mg) was obtained from Compound (86) in a manner similar to Example 1.

¹H-NMR (300 MHz, DMSO-d₆, δ): 2.78 (1H, dd, J=14.0, 5.6 Hz), 2.95 (1H, dd, J=14.0, 7.7 Hz), 3.06 (3H, s), 4.34 (1H, d, J=6.4 Hz), 5.04 (2H, s), 6.40 (1H, d, J=16.0 Hz), 6.86 (2H, d, J=8.7 Hz), 7.04 (2H, d, J=8.7 Hz), 7.21 (1H, d, J=16.0 Hz), 7.23 (2H, d, J=8.1 Hz), 7.32-7.24 (7H, m);

MASS (ES+): m/e 404 (M+1).

Example 15

Compound E15 (844 mg) was obtained from Compound (94) in a manner similar to Example 1.

5 ^1H -NMR (300 MHz, DMSO- d_6 , δ): 2.95 (6H, s), 6.40 (1H, d, $J=8.4$ Hz), 6.50 (1H, d, $J=15.4$ Hz), 6.79 (2H, d, $J=8.8$ Hz), 7.26 (2H, d, $J=8.8$ Hz), 7.39-7.70 (8H, m), 7.99-8.05 (2H, m), 9.26 (1H, d, $J=8.4$ Hz);

MASS (ES+): m/e 416.16 (M+1).

10 Example 16

Compound E16 (440 mg) was obtained from Compound (99) in a manner similar to Example 1.

^1H -NMR (300 MHz, DMSO- d_6 , δ): 2.01 (3H, s), 2.94 (6H, s), 6.08 (1H, d, $J=9.1$ Hz), 6.51 (1H, d, $J=15.4$ Hz), 6.76 (2H, d, $J=8.8$ Hz),
15 7.15 (2H, d, $J=8.8$ Hz), 7.31-7.37 (1H, m), 7.40-7.57 (4H, m), 8.77 (1H, d, $J=9.1$ Hz);

MASS (ES+): m/e 354.20 (M+1).

The compounds obtained by the above-mentioned Preparations
20 and Examples are listed in the following Table 2 (including Tables 2-1 to 2-13) and Table 3 (including Tables 3-1 and 3-2).

Table 2

Table 2-1









Compound (1)	Compound (2)
	
Compound (3)	Compound (4)
	
Compound (5)	Compound (6)
	
Compound (7)	Compound (8)
	

Table 2-2









Compound (9)	Compound (10)
	
Compound (11)	Compound (12)
	
Compound (13)	Compound (14)
	
Compound (15)	Compound (16)
	

Table 2-3









Compound (17)	Compound (18)
	
Compound (19)	Compound (20)
	
Compound (21)	Compound (22)
	
Compound (23)	Compound (24)
	

Table 2-4









Compound (25)	Compound (26)
	
Compound (27)	Compound (28)
	
Compound (29)	Compound (30)
	
Compound (31)	Compound (32)
	

Table 2-5









Compound (33)	Compound (34)
	
Compound (35)	Compound (36)
	
Compound (37)	Compound (38)
	
Compound (39)	Compound (40)
	

Table 2-6









Compound (41)	Compound (42)
	
Compound (43)	Compound (44)
	
Compound (45)	Compound (46)
	
Compound (47)	Compound (48)
	

Table 2-7









Compound (49)	Compound (50)
	
Compound (51)	Compound (52)
	
Compound (53)	Compound (54)
	
Compound (55)	Compound (56)
	

Table 2-8









Compound (57)	Compound (58)
	
Compound (59)	Compound (60)
	
Compound (61)	Compound (62)
	
Compound (63)	Compound (64)
	

Table 2-9









Compound (65)	Compound (66)
	
Compound (67)	Compound (68)
	
Compound (69)	Compound (70)
	
Compound (71)	Compound (72)
	

Table 2-10









Compound (73)	Compound (74)
	
Compound (75)	Compound (76)
	
Compound (77)	Compound (78)
	
Compound (79)	Compound (80)
	

Table 2-11









Compound (81)	Compound (82)
	
Compound (83)	Compound (84)
	
Compound (85)	Compound (86)
	
Compound (87)	Compound (88)
	

Table 2-12









Compound (89)	Compound (90)
	
Compound (91)	Compound (92)
	
Compound (93)	Compound (94)
	
Compound (95)	Compound (96)
	

Table 2-13




Compound (97)	Compound (98)
 <chem>CN(C)c1ccc(cc1)C2C(=O)N(C2)C3=CC=C(C=C3)C=C4C(=O)OCC4</chem>	 <chem>CN(C)c1ccc(cc1)C2C(=O)N(C2)C3=CC=C(C=C3)C=C4C(=O)O4</chem>
Compound (99)	
 <chem>CN(C)c1ccc(cc1)C2C(=O)N(C2)C3=CC=C(C=C3)C=C4C(=O)NCO4</chem>	

Table 3

Table 3-1

















Compound E1	Compound E2
	
Compound E3	Compound E4
	
Compound E5	Compound E6
	
Compound E7	Compound E8
	

Table 3-2

Compound E9	Compound E10
	
Compound E11	Compound E12
	
Compound E13	Compound E14
	
Compound E15	Compound E16
	


INDUSTRIAL APPLICABILITY

According to the invention, a compound having a potent inhibitory effect on the activity of histone deacetylase and a pharmaceutical composition containing said compound as an active ingredient can be provided. The compound is useful as an active ingredient of an immunosuppressant and an antitumor agent, and useful as a therapeutic or prophylactic agent for diseases such as inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections, tumors, etc.

This application is based on the patent application No. 2003900587 filed in Australia, and the contents of which are incorporated hereinto by reference.

CLAIMS

1. A compound having the following formula (I):




wherein

- 5 R^1 is lower alkyl optionally substituted with one or more suitable substituent(s);
 aryl optionally substituted with one or more suitable substituent(s); or
 fused ring,
- 10 R^2 is acylamino or optionally protected hydroxy,
 L^1 is lower alkenylene, and
 R^3 is hydroxyamino,
 or a salt thereof.
- 15 2. The compound of claim 1, wherein
 R^1 is lower alkyl optionally substituted with
 aryl(lower)alkoxyaryl;
 aryl optionally substituted with the group(s) selected from
 lower alkoxy, halogen, aryl, aryl(lower)alkoxy and mono- or
 20 di-substituted amino; or
 fused ring, and
 R^2 is acylamino selected from lower alkylcarbonylamino, lower
 alkylsulfonylamino and arylcarbonylamino; or
 hydroxy optionally protected with lower alkyl,
 25 or a salt thereof.
- 30 3. A pharmaceutical composition containing the compound of claim
 1 or 2 as an active ingredient, in association with a
 pharmaceutically acceptable, substantially non-toxic carrier or
 excipient.

4. The compound of claim 1 or 2 for use as a medicament.

5. A histone deacetylase inhibitor comprising a compound having the following formula (I):

5



wherein

R^1 is lower alkyl optionally substituted with one or more suitable substituent(s);
aryl optionally substituted with one or more suitable substituent(s); or
fused ring,

10

R^2 is acylamino or optionally protected hydroxy,

L^1 is lower alkenylene, and

R^3 is hydroxyamino,


15 or a salt thereof.

6. A method for inhibiting histone deacetylase, comprising using the compound (I) of claim 5.

20 7. Use of the compound (I) of claim 5 for the manufacture of a medicament for inhibiting histone deacetylase.

8. A pharmaceutical composition for treating or preventing inflammatory disorders, diabetes, diabetic complications,

25 homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors, which comprises a compound of the following formula (I) as an active ingredient:



wherein

R¹ is lower alkyl optionally substituted with one or more suitable substituent(s); aryl optionally substituted with one or more suitable substituent(s); or fused ring,

5 R² is acylamino or optionally protected hydroxy,

L¹ is lower alkenylene, and

R³ is hydroxyamino,

or a salt thereof.

10 9. A method for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors, which comprises administering an effective amount of
15 the compound (I) of claim 1 to a human being or an animal.

10. Use of the compound (I) of claim 1 for the manufacture of a medicament for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia,
20 fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors.

11. A commercial package comprising the pharmaceutical
25 composition of claim 8 and a written matter associated therewith, the written matter stating that the pharmaceutical composition may or should be used for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia
30 (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 August 2004 (26.08.2004)

PCT

(10) International Publication Number
WO 2004/071401 A3

(51) International Patent Classification⁷: **C07C 259/06**,
311/05, C07D 317/48, A61K 31/165, 31/18, 31/335

(21) International Application Number:
PCT/JP2004/001437

(22) International Filing Date: 10 February 2004 (10.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2003900587 11 February 2003 (11.02.2003) AU

(71) Applicant (for all designated States except US): **FUJISAWA PHARMACEUTICAL CO., LTD.** [JP/JP];
4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka
5418514 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **URANO, Yasuharu** [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd.,
4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka
5418514 (JP). **HOSAKA, Mitsuru** [JP/JP]; c/o Fujisawa
Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome,
Chuo-ku, Osaka-shi, Osaka 5418514 (JP). **KAMIJO,**
Kazunori [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd.,
4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka
5418514 (JP).

(74) Agent: **TAKASHIMA, Hajime**; Fujimura Yamato Seimei
Bldg., 2-14, Fushimimachi 4-chome, Chuo-ku, Osaka-shi,
Osaka 5410044 (JP).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).


Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
14 October 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HYDROXAMIC ACID DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS (HDCA)



(57) Abstract: A compound
having the following formula
(I): wherein R¹ is lower alkyl
optionally substituted with one or
more suitable substituent(s); aryl
optionally substituted with one
or more suitable substituent(s);
or fused ring, R² is acylamino or
optionally protected hydroxy, L¹ is

lower alkenylene, and R³ is hydroxyamino, or a salt thereof. The compound is useful as an inhibitor of histone deacetylase.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP2004/001437

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C259/06 C07C311/05 C07D317/48 A61K31/165 A61K31/18
A61K31/335

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/22577 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH); BAIR KENNETH WALTER () 21 March 2002 (2002-03-21) cited in the application page 69, compound n. 244; claims	1,10
A	WO 01/38322 A (METHYLGENE INC) 31 May 2001 (2001-05-31) cited in the application claims 1-48	1,10
P,A	WO 03/087066 A (SK CHEMICALS CO LTD ; IN2GEN CO LTD (KR); KIM DAE-KEE (KR); KIM JAE-SU) 23 October 2003 (2003-10-23) claims 1-6; examples 1-3,5-7,13-17	1,10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 August 2004

Date of mailing of the international search report

30/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rufet, J

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/001437

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 9
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 9 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP2004/001437

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0222577	A	21-03-2002	AU 8212901 A	26-03-2002
			BR 0113669 A	03-06-2003
			CA 2420899 A1	21-03-2002
			CN 1450991 T	22-10-2003
			CZ 20030573 A3	18-06-2003
			WO 0222577 A2	21-03-2002
			EP 1318980 A2	18-06-2003
			HU 0300880 A2	28-08-2003
			JP 2004509105 T	25-03-2004
			NO 20030867 A	25-02-2003
			SK 2422003 A3	11-09-2003
			US 2004024067 A1	05-02-2004
			US 2003018062 A1	23-01-2003
WO 0138322	A	31-05-2001	AU 1876801 A	04-06-2001
			CA 2391952 A1	31-05-2001
			EP 1233958 A1	28-08-2002
			WO 0138322 A1	31-05-2001
			JP 2003514904 T	22-04-2003
			US 6541661 B1	01-04-2003
WO 03087066	A	23-10-2003	WO 03087066 A1	23-10-2003
			KR 2003081173 A	17-10-2003

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.